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CHAPTER I
INTRODUCTION
Since the inception of nanotechnology in the 1980s, nanoparticles (NP) have been explored as
more efficient and less toxic drug delivery systems (DDS). Many of these approaches have used
organic polymers as their core structures such as cyclodextrin nanosponges (Torne, Darandale,
Vavia, Trotta & Cavalli, 2013) and biodegradable polymers (Vila, Sánchez, Tobío, Calvo &
Alonso, 2002) while others synthesized homologs of naturally occurring molecules such as
liposomes (Batist et al., 2001) and self-assembling peptides (Boopathy & Davis, 2014). Another
group of NPs have used protein cores around which to build their DDSs. Perhaps the most
intriguing are albumin-based NPs.
Albumin provides an excellent core around which to design a DDS. It is biodegradable,
nontoxic, and easily customizable due to a large number of accessible functional groups on its
surface. More importantly, albumin is a natural mode of transport for both endogenous and
exogenous hydrophobic molecules (Elsadek & Kratz, 2012; Elzoghby, Samy & Elgindy, 2012;
Kratz, 2008; Peters, 1996).
Albumin-Based Nanoparticles
Several approaches have successfully produced nano-scale albumin-based DDSs.
Discussed below are just a few to demonstrate the breadth of methodologies developed.
Desolvation, developed by the Langer group, uses organic solvents such as ethanol and
acetone to dehydrate drug-loaded albumins. Sedimented protein is polymerized via a cross1
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linking agent such as glutaraldehyde to provide stability before re-hydration (Langer et al., 2008;
Weber, Coester, Kreuter & Langer, 2000). Human serum albumin (HSA) NPs were prepared
using desolvation techniques and loaded with the chemotherapeutic doxorubicin. The NPs were
further modified by the addition of trastuzumab as a targeting mechanism. Targeted NPs showed
a cell viability of 20.1%, suggesting successful uptake and drug release (Anhorn, Wagner,
Kreuter, Langer & von Briesen, 2008).
Spray-drying is accomplished by passing a protein solution through a wire mesh at
elevated temperatures to generate a powder. Smooth, spherical bovine serum albumin (BSA)
NPs were successfully prepared at temperatures between 80-120oC in the presence of
Tween®-80. The morphology of the NPs was dependent on the surfactant content. Tween-80,
often used as an excipient in protein formulations, produced the most homogenous and spherical
NPs. NP size was most dependent on mesh size. The particle size increased as mesh size
increased. A 4.0 µm mesh generated NPs 733 nm in diameter while those from a 7.0 µm mesh
were 2609 nm (Lee, Heng, Ng, Chan & Tan, 2011).
Thermal gelation can be viewed as a two-phase process. Albumins are thermally
denatured and then non-covalently linked via electrostatic and hydrophobic/hydrophilic
interactions (Boye, Alli & Ismail, 1996). This process was successfully applied to the loading of
BSA-dextran and BSA-dextran-chitosan NPs with doxorubicin. Covalent BSA-dextran
conjugates were held at 80oC in the presence of chitosan. The resulting NPs consisted of chitosan
and dextran arms stretching out from an albumin core. Administration of doxorubicin-loaded
NPs to cancerous mice showed an increased survivability rate as compared to free doxorubicin
indicating an increased cell permeability for the conjugate (Qi, Yao, He, Yu & Huang, 2010).
Each of these systems has a distinct advantage in that they each provide a degree of fine control
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over the final particle size via alteration of easily monitored parameters (pH, reaction time,
solvent content, reagent concentration, equipment used).
The drawbacks of each approach provide cause for concern. Reliance on organic solvents
and surfactants in the production of materials to be administered to living beings must be
minimized to avoid toxicity. Thermal denaturation and a highly-altered surface from extensive
cross-linking may elicit an immune response as well as potentially alter biological activity.
Necessarily high temperatures place limitations on potential drug candidates.
nabTM Technology and Abraxane®
Abraxane®, a paclitaxel (PTX) formulation, is the most successful albumin-based NPs to
date. Approved in 2005 by the US Food and Drug Administration for the treatment of metastatic
breast cancer, it is recognized as the first protein-based NP on the market. American Biosciences,
Inc., now Celgene Corporation, developed a method for producing nanoparticle albumin-based
(nabTM) carriers of which Abraxane was the first application (Desai, 2008).
The passage of an aqueous stream of HSA and hydrophobic drug through a high-pressure
jet forms the nab NP. Albumins adsorb to one another to which drugs preferentially bind. Upon
administration, the 130-nm shell dissociates (Elsadek & Kratz, 2012; Elzoghby et al., 2012;
Kratz, 2008).
Abraxane is the trade name for the complexation of PTX and nab albumin. This product
was developed as a response to the problems associated with Taxol®, the original formulation for
stand-alone PTX. In the absence of nab, PTX requires Cremophor® EL (CrEL), a polyethoxylated castor oil, for solubilization. This necessitates infusion times of up to three hours and
pre-medication with corticosteroids and antihistamines to reduce the chance of hypersensitivity
reactions. Additionally, PTX delivery was hindered by micellular CrEL formation. Upon
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administration of Taxol, CrEL aggregates, creating a hydrophobic environment into which PTX
readily diffuses. CrEL toxicity can be quite severe as it presents as neutropenia and sometimes
permanent neuropathy (Hawkins, Soon-Shiong & Desai, 2008).
The much simpler formulation of Abraxane, consisting of only HSA and PTX, allows for
shorter infusion times (30 minutes), no pre-medicating, a reduced risk of hypersensitivity
reactions, and no toxicity (Hawkins et al., 2008). Studies have reported 33% increase of
intracellular PTX concentrations with Abraxane (Gradishar et al., 2005). Dissociation of
Abraxane upon administration results in accumulation of albumins into tumor cells via both the
passive targeting phenomenon of the enhanced permeation and retention effect and active
targeting via albondin (gp60) endocytosis. It was determined that cancerous cells are able to
acquire up to 17% of a single dose of 111In-labeled albumin, indicating a degree of preference by
tumors for albumin (Stehle et al., 1999). By combining albumin’s two-fold tumor targeting with
the ability of Abraxane to house multiple PTX, an increased drug concentration was
unsurprising.
This same housing ability allows for Abraxane to be administered at a 50% higher dose
than Taxol. PTX introduced into the bloodstream via the Taxol is unbound and free to interact
with both cancerous and healthy tissues. nab technology provides a means of sequestering the
chemotherapeutic until it is inside its intended target. This sequestration results in decreased
toxicity, higher dosage rates, and a higher therapeutic window for Abraxane.
The wider application of nab technology is questionable. It has proven to be an effective
chemotherapy due to its high drug load, solubility, and improved administration. The gp60
targeting mechanism is not universal for all drugs and the dissolution of Abraxane would require
a targeting mechanism for each individual protein to be as effective for non-chemotherapeutics.
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Additionally, dissolution of the nab NPs in the bloodstream results in the infusion of a large
quantity of individual albumin molecules which may greatly impact the osmotic pressure.
Albumin-Drug Conjugates
The techniques described result in polymerized albumins which provide a framework to
which the drug is non-covalently attached. Albumin-drug conjugates remain monomeric and
provide a means of solubilizing and increasing circulation time for bound ligands. Two
approaches have been employed to produce these conjugates. In the first, a drug is covalently
attached to albumin via a surface residue. In the second, the drug is covalently attached to a
ligand of albumin. Upon administration of this complex, the ligand binds to a high affinity site of
endogenous albumin, effectively non-covalently binding the drug.
The first albumin-drug conjugate to reach phase I/II clinical studies was a complex with
the antimitotic cancer drug methotrexate. Similar to PTX, methotrexate suffered from poor
solubility and severe toxicity associated with the drug itself and components of the formulation.
For the conjugate, methotrexate was covalently attached to HSA via lysine residues (Stehle,
Sinn, Wunder, Schrenk, Schütt et al., 1997). Clinical results for this complex were somewhat
promising in that three out of 17 patients showed a positive response to therapy. Other factors,
such as stomatitis, limited the dosage rates, and potentially limited the efficacy of treatment
(Kratz, 2008).
Long-lasting insulin (Levemir®) for the treatment of both type 1 and type 2 diabetes is a
prime example of the second type of albumin-drug conjugate. Novo Nordisk, Inc. developed a
method for producing recombinant human insulin in which the C-terminus had been shortened
by elimination of the B-chain terminal threonine. This excision allowed access to an adjacent
lysine which was covalently attached to myristic acid. Upon administration, the insulin-myristic
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acid conjugate binds to albumin, resulting in an increase in circulatory half-life from four to six
minutes for native recombinant insulin to five to seven hours for the conjugate (Elsadek & Kratz,
2012; Keating, 2012).
Albumin-drug conjugates are attractive in their reasonably simple production protocols,
requiring no modifications of the protein outside of the attachment of the drug. While attachment
to the albumin provides an answer for solubilization, it does not necessarily protect the ligand
from the host. In the event of an immune response, the drug is susceptible to attack from
immunogenic agents which could result in early elimination, degradation of the therapeutic, or
dissection of the conjugate. If the drug were to be cleaved from the albumin before it reaches the
site of action, a potentially toxic molecule would be released into the bloodstream to interact
with healthy tissues.
Serum Albumin
Physiology
The robust nature of albumin, a highly-conserved protein found in the serum of all
mammals, has singled it out as a potential DDS component. It is a 66 kDa monomer produced by
the liver in quantities up to 12 g/day with a circulatory half-life of 20 days. Albumin can be found
in high quantities in skin, muscle, liver, and the gut as well as almost all bodily fluids (Lundblad,
2012; Peters, 1996). Its high production rate and long half-life make albumin the most abundant
protein in the serum.
Albumin is able to play a diverse set of roles in the body. Arguably its most important
function, albumin is the body’s main control on osmotic pressure (Table 1). Determined by the
number of particles in a system, not their size, osmotic pressure is the driving force between
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tissues and blood. Despite albumin being many times smaller than fibrinogen, it is found at such
a high concentration that it accounts for 79% of the osmotic pressure (Guyton & Hall, 2006).
Table 1. Contribution of the Major Classes of Serum Proteins to Osmotic Pressure (Guyton &
Hall, 2006).

Protein
Class

Average
MW
(kDa)

Serum
Concentration
(mM)

Osmotic
Pressure
(mm Hg)

% Total
Osmotic
Pressure

Albumin
Globulins
Fibrinogen

66
140
400

0.68
0.17
0.0075

21.8
6
0.2

79
20
1

This dependence on albumin as an osmotic regulator must be taken into account when
designing a DDS. A drastic increase in albumin concentration associated with a high dose of
albumin-bound drug would be accompanied by a drastic increase in osmotic pressure. This spike
would cause down-regulation of albumin gene-expression to compensate (Pietrangelo, Panduro,
Chowdhury & Shafritz, 1992). Decreased levels of native, unmodified albumin may lead to a
build-up of fatty acids, heavy metals, drugs, and their metabolites.
Clinical Applications
Albumin was first explored as a therapeutic agent during World War II. Albumin
solutions were administered as plasma expanders to wounded soldiers to minimize the effects of
blood loss on the battlefield. The first purification method involved multiple rounds of lowtemperature precipitations with ethanol to separate the protein components of blood. Albumin
was the fifth precipitate in the process and was originally deemed “Cohn Fraction V” (Cohn et
al., 1946; Peters, 1996). The peptide sequence of BSA was first published by Brown (1975)
while that of HSA was later independently reported by the Brown and Kostka labs (Behrens,
Spiekerman & Brown, 1975; Meloun, Morávek & Kostka, 1975). Since these initial works,
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albumin has become a staple of hospitals and clinics. Unmodified albumin is still used as a
plasma expander to aid in post-operative recovery and for treatment of shock and burns. It is also
used to treat patients suffering from hypoalbuminemia, specifically those with acute liver failure.
In these cases, the liver is unable to produce the requisite amount of albumin and the body
requires supplementation to maintain normal functionality (Lundblad, 2012). It has also been
developed as a protein-based resin for sealing wounds by CryoLife, Inc. BioGlue® contains
compartments of aqueous glutaraldehyde and BSA solutions. These are mixed in the syringe tip
during application and allowed to bond in situ. The resin is a matrix of highly cross-linked
albumin strong enough to hold tissues together during the healing process and safe enough to be
used internally ("CryoLife: BioGlue Instructions for Use," 2017).
Structural Basis for Ligand Binding
Albumins contain approximately 585 amino acids arranged in a highly helical heartshaped tertiary structure (Figure 1). Three similar domains (I, II, and III) are each subdivided
into subdomains A and B. Each domain is composed of 10 helices with six in subdomain A and
four in subdomain B. Each subdomain is connected by a long loop. Conformational flexibility is
conferred by helical bending and subdomain orientation is controlled by the movement of the
loops. These types of movements open and close the various binding sites dotted throughout the
structure.
While albumin is extremely flexible, the core structure is maintained via 17 disulfide
bridges. Subdomain A is stapled together by four of these while two bridges stabilize subdomain
B. The sole exception is Subdomain IA, which contains only three cystine bridges (Bujacz,
2012).
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Figure 1. Crystal structure of human serum albumin. (a) Space-filling model and (b) Ribbon
structure highlighting the three domains and heart-shaped structure. Domains I (blue), II
(yellow), and III (red) are held together by 17 disulfide bridges (gray). PDB ID: 1E7I
(Bhattacharya, Grüne & Curry, 2000). All crystal structure images were prepared using UCSF
Chimera (Pettersen et al., 2004) and rendered with POV-Ray ("Persistence of Vision Pty.
Ltd.: Persistence of Vision (TM) Raytracer," 2004).
Binding sites. In addition to its role in controlling osmotic pressure, another crucial
function of albumin is its ability to bind a wide variety of ligands including fatty acids, heavy
metals, drugs, and drug by-products (Figure 2). Discussed here are just a few of the many
binding sites on albumin.
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Figure 2. A selection of albumin binding sites. Fatty Acids are represented as yellow
hydrophobic tails with red hydrophilic heads. PDB ID: 1E7I (Bhattacharya et al., 2000).
Fatty acid sites. Several sites have been identified for long- and medium-chain fatty acids
(Ashbrook, Spector & Fletcher, 1972; Ashbrook, Spector, Santos & Fletcher, 1975; Bhattacharya
et al., 2000). A preference for saturated, long-chain fatty acids was determined by examining
fatty acid content and association constants. Oleic (18:1, 33%), palmitic (16:0, 25%) and linoleic
acid (18:2, 20%) made up a majority of the bound fatty acid content of HSA. Five others
accounted for another 12.5% and ranged between C14-C20 and zero to four degrees of
unsaturation (A. Saifer & Goldman, 1961). Examining a series of fatty acids ranging from C6C18 and zero to two degrees of unsaturation confirmed this preference for saturated, long-chain
fatty acids. Affinity increased with carbon count and decreased as double bond content increased
(Spector, 1975). As in the case of Levemir, this binding site allows for tailoring of a drug
conjugate to take advantage of an innate function of albumin to form a DDS in vivo. The lack of
modifications to the protein allow it to maintain functionality and avoid degradation.
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Cys34. A single free thiol found at residue 34 has been reported to participate in covalent
interactions with a variety of drugs and their metabolites, including bucillamine derivatives
(Narazaki, Hamada, Harada & Otagiri, 1996), nitrogen mustards (Noort, Hulst & Jansen, 2002),
and the reactive acetaminophen metabolite, N-acetyl-p-benzoquinoneimine (LeBlanc, Shiao,
Roy & Sleno, 2014). This residue is on the surface of the molecule, slightly buried in a shallow
cleft between two α-helices positioned well away from the two main drug binding sites. The
accessibility of Cys34 provides a great deal of control over conjugation of albumin to other
molecules. Given that it is the only sulfhydryl available, this allows for chemoselective, covalent
surface modification.
The N-terminus and the Multi-metal binding site. Many species of albumin, specifically
HSA and BSA, employ the X-Y-His motif at the N-terminus (NTS). This configuration allows
for high affinity binding of Cu(II) on the order of 1 pM (Rózga, Sokołowska, Protas & Bal,
2007). This strong association between the NTS and Cu(II) must be taken into account during
DDS development. Cu(I) is a catalyst for a set of biorthogonal reactions involving azides and
alkynes which will be discussed in more detail in other sections.
A secondary metal interaction site has been found. Deemed the Multi-metal binding site,
this area is known to interact with Cu(II), Ni(II), Zn(II), and Cd(II), however, none of these
species bind with high affinity. Typically, metal cations are not bound until the NTS has been
fully saturated (Bal, Christodoulou, Sadler & Tucker, 1998). Due to low affinities and little
impact on the NTS, this site has been largely ignored in favor of a better understanding of the
high-affinity NTS interaction with Cu(II).
Drug Site II (DS2). The two main drug binding sites of albumin were initially
characterized by Sudlow et al. (1975, 1976). One site has been deemed Sudlow Site II or Drug
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Site II. It is a small, compact single chamber with a patch of polar residues at the entrance to the
cavity (Figure 3). Tyr411, Arg410 and Ser489 line the mouth of the site, serving as the only
polar residues in the entire space.

Figure 3. Structure of Drug Site II in human serum albumin. Polar residues (green) lining the
mouth of the cavity are the only polar features of DS2. PDB ID: 2VDB (Lejon, Cramer &
Nordberg, 2008).
A lack of hydrophilicity in the pocket is mirrored in its ligands which are small
hydrophobics with a terminal polar group (Table 2) (Yamasaki, Chuang, Maruyama & Otagiri,
2013). The hydrophilic head, typically a carboxylic acid, is used to anchor the molecule in the
pocket. This also leads to a high degree of stereospecificity for ligand orientation. By no means a
flexible site, DS2 has shown the ability to make slight adjustments to accommodate side-chain
phenyl groups (Ghuman et al., 2005; Yamasaki et al., 2013).

DS1 Ligands

DS2 Ligands

Table 2. Example Ligands for Drug Site I and Drug Site II (Ghuman et al., 2005; Q. Wang, Zhang & Ji, 2014; Yamasaki et al., 2013).
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Drug Site I (DS1). Drug Site I or Sudlow Site I is a large, multi-chamber, mostly apolar
pocket with a few polar features that are key to the binding of ligands (Figure 4). A polar
environment is formed at the entrance to the cavity by Lys195, Lys199, Arg218, and Arg222.
Three residues are buried deep into the bottom of the site which help to orient molecules
(Tyr150, His242, Arg257). Ile264 splits the large chamber, giving a total of three subsites for
binding. Additionally, Trp214 resides near the mouth of the cavity. While this may participate in
hydrogen bonding with ligands and play a role sterically, it also serves as an innate fluorescent
probe for studying drug interactions (Ghuman et al., 2005; Yamasaki et al., 2013).

Figure 4. Structure of Drug Site I in human serum albumin. Polar residues (pink) at the entrance
and back (orange) of the cavity are able to hydrogen bond with ligands. Ile264 (purple) divides
the chamber into smaller subsites. Trp214 (red) provides an intrinsic probe for ligand binding.
PDB ID: 2VDB (Lejon et al., 2008).
DS1 has been called a “large and flexible region.” It is able to bind a wide range of
ligands, often more than one at a time, and is not stereospecific (Kragh-Hansen, 1988).
Molecules that show a high affinity for DS1 are typically large, flat, and aromatic with at least
one terminal and one internal polar functional group (Table 2). Flat molecules are preferred for
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DS1 due to Leu238 and Ala291 which are able to snugly fit the molecule into place. Terminal
polar moieties are needed to interact with the entryway residues while the internal polar group
interacts with the buried polar residues (Ghuman et al., 2005; Yamasaki et al., 2013).
While each of these sites exhibits preferential binding for certain types of molecules, they
are by no means exclusive for those molecules. Once the preferred site is filled, additional
molecules are often able to bind with lower affinities to other sites. In the case of naproxen,
crystal structures revealed three separate binding sites. DS2 was the preferred site as it was the
only site consistent between bovine, equine, and leporine serum albumins. Additional naproxen
were found in a fatty acid site and DS1 (Bujacz, Zielinski & Sekula, 2014).
Albumin Metabolism
Albumin has a half-life of 20 days, passing through circulation thousands of times before
being lysosomally degraded. The pathways used to evade early degradation, delivery of its
ligand payload, and ultimate catabolism provide useful knowledge for the informed design of
DDSs.
The Megalin/Cubilin complexes have been implicated as role players in saving albumin
from elimination through the kidneys. Cubilin, an extracellular protein, utilizes the
transmembrane protein megalin to shuttle albumin into the intracellular space. Mice missing one
or both of these proteins showed decreased albumin reabsorption, strongly suggesting a role in
albumin recycling (Christensen, Birn, Storm, Weyer & Nielsen, 2012).
Similar conclusions were drawn in the case of the neonatal Fc receptor (FcRn).
Immunoglobulin G (IgG) binds FcRn as a means to cross the placental barrier. Co-elution of the
IgG-FcRn complex unexpectedly coupled with albumin was the first indication of interaction.
Studies with FcRn deficient mice found a 40% decrease in albumin serum concentration, owing
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to the elimination of albumin rather than the transmembrane movement provided by FcRn.
Under acidic conditions, such as those experienced throughout the lysosomal pathway, FcRn
binds with high affinity to both albumin and IgG and escorts them to a more neutral environment
(Kim et al., 2006; Larsen, Kuhlmann, Hvam & Howard, 2016; Merlot, Kalinowski &
Richardson, 2014). FcRn clearly plays a key role in the long half-life of albumin by way of
rescuing the protein from degradation.
Glycoproteins of 30 kDa (gp30) and 18 kDa (gp18) have been shown to play a role in
albumin catabolism. While native albumin appears able to escape elimination through the
kidneys via the Megalin/Cubilin complex and FcRn pathways, damaged albumins are tagged by
gp30 and gp18. The affinities of these proteins for altered albumins are 1000-fold stronger than
for native albumin. Alterations are often due to oxidative damage or non-enzymatic
glycosylation. Upon binding, the sequestered albumin is ushered to sites of degradation (Larsen
et al., 2016; Schnitzer, Sung, Horvat & Bravo, 1992). The albumin is lysosomally catabolized
and the amino acids re-enter the cycle of protein synthesis (Stehle, Sinn, Wunder, Schrenk,
Stewart et al., 1997).
The most extensively studied albumin receptor is gp60. This receptor is common in
continuous endothelia from various tissues. It selectively binds albumin and with the help of
caveolin-1, endocytoses the protein (Schnitzer, 1992). In healthy cells, albumin uses this
pathway to migrate between the bloodstream and tissue (Merlot et al., 2014).
This is not the case in cancerous cells. The fate of albumin and the mechanism of
chemotherapy release are not fully known. Studies focused on the cellular uptake of Abraxane
found that the endocytosis of albumin was accompanied by a spike in the concentration of
osteonectin. It is postulated that osteonectin binds to albumin, tagging it for degradation which
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releases paclitaxel in the process (Desai, 2008; Hawkins et al., 2008; Tiruppathi, Song,
Bergenfeldt, Sass & Malik, 1997).
In addition to gp60 endocytosis, the enhanced permeation and retention effect must be
taken into account when considering cancerous cells. This is the passive trapping of
macromolecules in tumor tissues. The cells are growing rapidly and the lymphatic system is
unable to maintain sufficient drainage which limits the ability of molecules to exit the tumor
cells. Macromolecules, especially albumins, build up in the cells and are ultimately catabolized
for protein synthesis and energy.
Studies have explored the ability of modified albumins to be endocytosed into tumor
cells. One study covalently attached a low molecular weight protamine fragment to
chemotherapeutic-loaded BSA NPs to facilitate transfer across the blood-brain barrier (Lin et al.,
2016). Despite the modification, BSA was still successfully taken into tumor cells.
Both pathways have been exploited as ingress for chemotherapeutics into cancerous
tissues. The advantages are two-fold. The chance of toxicity due to free ligand is greatly reduced
when bound to albumin which also provides an innate targeting mechanism.
Human vs. Bovine Serum Albumin
To date, most clinical-use albumin formulations have been HSA-based. However, BSA
provides an alternative to address many concerns associated with a human blood-borne protein.
The main concern with using any human-derived blood product is the possibility of
disease. Human immunodeficiency virus, Hepatitis, Creutzfeldt-Jakob Disease, and West Nile
Virus are all potential pathogens that may be transferred with blood products. Despite the
stringent protocols employed to eliminate and avoid these blood-borne diseases, the stigma of a
formulation containing a human blood-based protein could decrease patient compliance.
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Additionally, the supply and cost of HSA is a cause for concern. The two main avenues
for gathering HSA are donations and recombinant technology. Donation based materials are
often in limited supply and can cause a fluctuation in availability. Recombinant human albumin
has been developed with rice (He et al., 2011) and yeast (Recombumin® from Albumedix Ltd.)
(Bosse et al., 2005). These have shown comparable safety, tolerability, pharmacokinetics, and
pharmacodynamics to native HSA but are quite expensive.
As a by-product of the cattle industry, BSA provides a much more cost-effective and
readily available substitute for HSA. A BLAST® search shows 76% homology between HSA and
BSA, suggesting a high degree of structural similarity.
Amino Acid Correlation
Comparison of amino acid composition shows strong correlations for key residue types.
The solubility of albumin is tied to the number of external charged amino acids. Approximately
31% of the residues on both species are charged, confirming similar solubilities.
A single free thiol can be found in both albumins. Of the 35 cysteine residues, 34 are
paired to make disulfide bridges that stabilize the tertiary structure of the three domains. This
unpaired cysteine allows for more controlled surface modification at a single, specific site.
Functionalization via surface modifications is a key attractant to albumin as a DDS.
Lysine residues are often the sites targeted as their terminal amino groups are able to react with a
variety of functional groups, allowing flexibility in the type of conjugation chemistry used. Both
species contain 59 lysines, each of which is a potential location to anchor a targeting molecule,
covalent drug conjugate, cross-linker, or polyethylene glycol chain.
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Structural Homology of DS1 and DS2
A closer look at the Sudlow sites reveals a strong contrast between species. The polar
residues of DS2 in HSA are present in BSA as residues Tyr410, Arg409, and Ser488 (Figure 5).
Conservation of the key residues implies similar binding capabilities and preferences for similar
molecules.

Figure 5. Comparison of Drug Site II between human and bovine serum albumin. (a) DS2 of
HSA. PDB ID: 2VDB (Lejon et al., 2008). (b) DS2 of BSA. PDB ID: 4OR0 (Bujacz et al.,
2014). Polar residues (green) are conserved between species.
As in HSA, DS1 of BSA contains a single tryptophan, Trp213. The polar features buried
in the cavity of DS1 are consistent between HSA and BSA (Tyr149, His241, and Arg256). Some
discrepancies are found at the entrance to DS1. The polar cluster of HSA is closely mimicked in
BSA (Arg194, Arg198, Arg217, and Lys221) (Figure 6). However, the substitution of arginines
for lysines may cause differences in binding capacities. The distal guanidinium group of arginine
allows for more hydrogen-bonding and stronger ligand interactions. The delocalized charge,
however, weakens the bonds with individual molecules (Li, Vorobyov & Allen, 2013).
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Sterically, the guanidinium R-group is bulkier than the terminal amine of lysine which may
hinder entry and exit from DS1 in BSA. Despite these discrepancies, interchange of these two
proteins should be possible.

Figure 6. Comparison of Drug Site I between human and bovine serum albumin. (a) DS1 of
HSA. PDB ID: 2VDB (Lejon et al., 2008). (b) DS1 of BSA. PDB ID:4OR0 (Bujacz et al., 2014).
External (pink) and internal (orange) polar residues are well-conserved between species.
Additionally, Trp (red) provides a native fluorophore in both forms of albumin.
Polyethylene Glycol (PEG)
Polyethylene glycol (PEG), a water-soluble polymer, is used in a wide variety of
industries for a wide variety of applications from control of the viscosity of printer ink to an antifoaming agent in food preparation to laxatives as pre-operative patient preparation. In laboratory
use, it has been employed as a protein precipitating agent as well as a means to facilitate cell
fusion (Zalipsky & Harris, 1997).
PEG is available in a wide range of sizes and functional groups. Entire companies have
been built around the production and customization of PEGs tailored for specific uses ("Creative
PEGworks: PEG Products," 2017; "JenKem Technology: PEG Products," 2017). PEGs from as
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small as 400 Da (PEG400) to as large as 40,000 Da (PEG40k) have been examined as possible
surfactants and DDS components.
PEG-Protein Nanoparticles
PEG has played a role in the development of several successful protein-based NPs (Table
3) (Haag & Kratz, 2006; "US Food and Drug Administration: Drug Approval Packages," 2017;
Veronese, Mero & Pasut, 2009). The regulatory approval of the first PEGylated enzymes,
Adagen® and Oncaspar®, in the 1990s was the turning point for the change of perspective
towards PEG as a building block for future DDSs rather than a mere additive to formulations
(Duncan & Veronese, 2009). As a result, more research has been done on the metabolism,
toxicity, and benefits of PEGylation.

20 kDa (2) Anti-VEGF aptamer

Macugen®

Cimzia®

Erythropoietin

Growth hormone
antagonist

Interferon α2a

40 kDa (2) Anti-TNF Fab’

30 kDa

5 kDa (46)

Somavert®

Mircera®

40 kDa

PEGASYS®

Valeant Pharmaceuticals
International Inc.
F. Hoffmann-La Roche
Ltd
UCB, Inc.

Age-related macular
degeneration
Anemia associated with
chronic kidney disease
Rheumatoid arthritis and
Crohn’s disease

2008

2007

2004

2003

2002

F. Hoffmann-La Roche
Ltd
Pharmacia & Upjohn
Company

2002

2001

Schering-Plough
Corporation
Amgen Inc.

1994

1990

Approval
Year

Sigma Tau
Pharmaceuticals Inc.

Sigma Tau
Pharmaceuticals Inc.

Company

Acromegaly

Hepatitis C

Neutropenia

Granulocyte-colony
stimulating factor

20 kDa

Neulasta®

Hepatitis C

Interferon α2b

12 kDa

PEG-INTRON®

Leukemia

5 kDa (69Asparaginase
82)

Oncaspar®

Indication
Severe combined
immunodeficiency disease

Protein

5 kDa (11Adenosine deaminase
17)

PEG MW
(count)

Adagen®

Trade Name

Table 3. Current Market-Available PEGylated Protein Products (Haag & Kratz, 2006; "US Food and Drug Administration: Drug
Approval Packages," 2017; Veronese et al., 2009).
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PEG Metabolism
Heavy PEGs (MW > 1000 Da) are minimally absorbed by the gastrointestinal tract. For
this reason, the oral administration of PEG conjugates is ineffective. The harsh environment of
the digestive system limits the types of conjugates that can be administered orally. PEG-protein
complexes risk damage due to enzymatic degradation before entering the bloodstream. For these
reasons, most PEGylated drugs are administered via injection or intravenously.
Increasing PEG molecular weight corresponds to an increased circulatory half-life. In a
study monitoring the distribution of 125I-labeled PEG between MWs of 6,000 Da (PEG6k) and
190,000 Da (PEG190k), urinary clearance decreased as molecular weight increased. PEG6k had
a half-life of 18 minutes following intravenous administration. PEG190k, nearly 30 times larger,
had a half-life of approximately 24 hours (Yamaoka, Tabata & Ikada, 1994). The size of the PEG
chain clearly has an effect on time retained by the body.
Evidence was found that PEG-protein conjugates were first broken down by degradation
of the protein followed by cleavage from the PEG backbone. Once separated, PEG is passed
through the kidneys while proteins are catabolized under normal pathways, producing non-toxic
metabolites (R. Webster et al., 2009). The safety of the remaining PEG must be examined to
determine the suitability of these conjugates as DDSs.
Toxicity
Toxicity has only been associated with extremely low molecular weight PEGs. Fatalities
have been reported in burn patients after treatment with an antimicrobial cream containing 95%
PEG300. It was found that in vivo, PEG400 and smaller were oxidized by alcohol dehydrogenase
into toxic diacid and hydroxyl acid metabolites in the blood, poisoning the patients. The rate of
oxidation decreased greatly with increased PEG size. The smallest PEG studied, ethylene glycol
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(MW 62 Da), was degraded 32 times faster than the largest, octaethylene glycol (MW 370 Da)
(Herold, Keil & Bruns, 1989). Another study administered PEG400 and smaller to mice and rats.
Doses of 10 mL/kg or less proved fatal (Bartsch, Sponer, Dietmann & Fuchs, 1976). Intravenous
administration of PEG1400 and larger showed no toxicity or negative effects in rabbits and dogs
(Working, Newman, Johnson & Cornacoff, 1997).
Advantages of PEGylation
As Table 3 details, several proteins have been successfully attached to PEGs of various
sizes. The benefits of PEGylation are most strongly tied to the hydrophilicity of PEG itself. This
hydrophilicity, due to the oxygen content of the PEG backbone, means that PEG and its
conjugates are highly soluble and highly hydrated in aqueous environments. It is estimated that
PEG is able to adsorb three to five water molecules per ethoxylene subunit, thus greatly
increasing the hydrodynamic volume of the backbone. Increased hydrodynamic volume results in
a molecule that appears too large to pass through kidney filtration (Figure 7). Avoidance of
elimination via normal pathways leads to increased circulatory half-life (Plesner, Fee, Westh &
Nielsen, 2011; Veronese et al., 2009).
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Figure 7. Diagram of a PEGylated protein nanoparticle. Covalent conjugation of PEG chains
onto the surface of a protein greatly increases the hydrodynamic volume of the NP, conferring
increased circulation lifetime and immunogenic masking.
Avoidance of degradation by immunogenic agents also increases the circulation half-lives
of these NPs. Chicken Immunoglobulin Y was administered to mice in native and PEGylated
forms. Protein conjugated with 3-13 PEG5k or PEG20k showed immune response levels drop to
as low as 1.6% detection (Gefen et al., 2013). PEGylation is able to mask bound protein from
immunogenic response as the antibodies are unable to sense the protein core due to steric
hindrance from the PEG backbones. This helps to protect the NP against damage and
degradation.
PEGylation confers a number of benefits to the attached protein core. However,
PEGylation may also be deleterious to the NP. The attachment of PEG is typically done through
covalent bonds with surface residues. Eliminating these charges and masking the protein surface
may lead to poor target and ligand recognition which, in turn, could greatly alter the biological
activity of the protein.
The effects of PEGylation on albumin stability were monitored using PEG chains ranging
from PEG5k to PEG60k attached to BSA at Cys34 via the thiol-ene reaction. Circular dichroism
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studies showed no loss of secondary structure after PEGylation. Upon application of heat, it was
found that attachment of PEG, slightly lowered the temperature of denaturation of 82.5oC for
unmodified BSA by 2-3oC. There was no direct correlation between the change of denaturation
temperature and PEG molecular weight. There does, however, appear to be a connection between
molecular weight and the temperature of aggregation. For PEGs between 10-40 kDa, aggregation
began at 81oC while unmodified BSA began to aggregate at 71oC (Plesner et al., 2011). It
appears that the stability of BSA is slightly compromised but the PEG backbone helps to stave
off aggregation.
It should be noted that while attaching many strands of small molecular weight PEG has
been successful, it has been proven to be more beneficial to use less PEGs with a total weight
equal to these small PEGs. The Williams group demonstrated that attaching two to five strands
of PEG30k to superoxide dismutase was more effective than 7-15 strands of PEG5k in
preserving biological activity, increasing lifetime and reducing immunogenicity (M. G. P. Saifer,
Somack & Williams, 1994).
“Click” Chemistry
“Click” chemistry denotes a series of reactions which are modular and give high yields.
Reaction conditions are simple and insensitive to water and oxygen. The stereospecificity of
these reactions is what makes them so attractive for bionconjugation. The final product is due
completely to the functional groups reacted. Groups attached to these reactive moieties may
enhance the reaction but may not change the final product (Kolb, Finn & Sharpless, 2001).
The basis for click chemistry begins with a modification of the Huisgen reaction between
azides and alkynes. This reaction was largely ignored because of the need for high temperatures
and pressures. The use of a Cu(I) catalyst as a way to run these reactions under less extreme

27
conditions paved the way for the rapid rise in popularity of click chemistry (Rostovtsev, Green,
Fokin & Sharpless, 2002; Tornøe, Christensen & Meldal, 2002). These reactions and their
applications have been extensively reviewed by Kolb et al. (2001) and Thirumurugan et al.
(2013).
Azide-Alkyne Cycloaddition (AAC)
Cu(I)-catalyzed AAC (CuAAC). The Cu(I)-mediated reaction between azides and
alkynes (Figure 8) is the prototypical click reaction. It is fast, high-yielding, and stereospecific,
giving only 1,4-disubstituted 1,2,3-triazoles. Reaction conditions do not require elevated
temperatures or pressures.

Figure 8. Cu(I)-catalyzed azide-alkyne cycloaddition. The reaction of a terminal azide with a
terminal alkyne in the presence of Cu(I) with a compliment of ligand, reducing agent and
suppressor reagent results in a single 1,4-disubstituted 1,2,3-triazole product. Kinetics may be
enhanced by incorporating an electron-withdrawing group at the R3 position.
The employment of a copper catalyst is accompanied by a variety of complimentary
reagents. The accelerating ligand chelates the copper and helps maintain the proper coordination
environment. The catalyst is more cost-effective as a Cu(II) salt and reduce which is reduced in
situ by an agent such as ascorbate. However, this reduction often results in reactive oxygen
species which may modify amino acid side chains. To counteract this, aminoguanidine is
included (Hong, Presolski, Ma & Finn, 2009).
Despite the high solubility and stability of these reagents at physiological pH, this form
of AAC is not ideal for production of albumin-based DDSs. As previously discussed, the N-
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terminus in many albumins is able to bind Cu(II) with an affinity of 1 pM. The bound Cu(II) will
be difficult to remove during work-up of the resulting NPs. All traces of copper must be removed
before introduction into a patient as additional, undesirable heavy metals are toxic to the host.
Cu(II) has been implicated in neurodegenerative diseases, including prion diseases and
Alzheimer’s disease (Rózga et al., 2007). While the copper catalyst and its compliment of
reagents are readily available and cost-effective, simpler AAC reactions have been developed.
Strain-promoted AAC (SPAAC). Copper-free click chemistry circumvents the need for
a Cu(I) catalyst by incorporating the alkyne into a strained ring such as a cyclooctyne or
cyclononyne (Figure 9a) (Agard, Prescher & Bertozzi, 2004). With a simple, unsubstituted
cyclooctyne, the reaction kinetics are considerably slower than those of CuAAC. Attachment of
electron withdrawing groups onto the ring adjacent to the alkyne has been used to increase
reaction rates. Difluoro- (Figure 9b) and Dibenzocyclooctynes (Figure 9c) returned rates back to
those of CuAAC without the need for a Cu(I) catalyst and have become the first choice for
SPAAC reactions (Ning, Guo, Wolfert & Boons, 2008; van Berkel et al., 2007).
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Figure 9. Strain-promoted azide-alkyne cycloaddition. (a) By incorporating the alkyne into a
strained ring system, the reaction with a terminal azide no longer requires a catalyst or the
compliment of reagents needed for CuAAC. The same 1,4-disubstituted 1,2,3-triazole product is
formed but with slower reaction kinetics. (b) Difluoro- and (c) Dibenzocyclooctynes have been
shown to increase the kinetics to rates comparable to CuAAC (Ning et al., 2008; van Berkel et
al., 2007).
Azides and alkynes are biorthogonal as both are virtually absent from nature. The sole
exceptions are azide-containing natural products found in toxic red algae on the Gulf Coast of
Florida. Additionally, both are virtually non-reactive with any naturally-occurring functional
group (Baskin & Bertozzi, 2009). This, coupled with the reduced toxicity due to the elimination
of the copper catalyst, make SPAAC an excellent candidate for conjugation chemistry with
albumin.
Thiol-ene Reactions
Thiol-ene reactions, while involving neither an azide nor an alkyne, are another class of
click chemistry (Figure 10). All of the criteria are met in that the reaction is simple and the
product formed is stereospecific and gives high yields (Lowe, 2010). This reaction is especially
applicable to proteins with exposed cysteine residues. The free thiol may be chemoselectively
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reacted with an alkene-containing linker to attach drugs or targeting molecules (Chalker,
Bernardes, Lin & Davis, 2009).

Figure 10. Thiol-ene reaction. (a) A thiol from an exposed cysteine may be reacted with an
alkene resulting in a thioether linkage. (b) A common form of the -ene used in these reactions is
the maleimide functional group.
The most common functional group employed for protein modification at cysteines is the
maleimide. Incorporation of the electron-deficient moiety into the molecule to be attached to the
protein allows for fast and easy modification under physiological conditions. For example, a
maleimide-methotrexate prodrug was developed as a treatment for arthritis (Fiehn, Kratz, Sass,
Müller-Ladner & Neumann, 2008). Upon intravenous administration, this prodrug binds to
Cys34 of HSA in vivo. The conjugate is later enzymatically cleaved, releasing a bioactive
derivative of methotrexate. The maleimide-cysteine reaction is rapid and selective, greatly
increasing the efficacy of the methotrexate treatment.
Summary
BSA provides an intriguing option to build a nano-scale DDS. It is highly soluble, with a
plethora of binding pockets, and a large number of surface residues which can be used for
customization without the need for recombinant methodologies. Its structural similarities with
HSA suggests a similar degree of effectiveness can be achieved when incorporated into any of
the published NP methodologies.
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A multitude of approaches have been attempted at formulating a successful albuminbased DDS. Each was successful at solubilizing a hydrophobic pharmaceutical in the presence of
albumin but flaws in each must be addressed to move forward. Only one albumin-based NP has
successfully made it to market. Abraxane, while effective, still requires an infusion of a large
dose of albumin into the bloodstream, potentially affecting the osmotic pressure and
subsequently the production of native albumin.
Several PEGylated proteins have been approved, but none are DDSs. PEGylation has
proven to be advantageous as it confers increased hydrodynamic volume which leads to
increased circulation lifetimes and decreased immune response. However, PEGylation may
slightly destabilize the protein at elevated temperatures and steric hindrance due to the attached
PEGs may negatively affect biological activity and cellular recognition.
The biorthogonality of SPAAC and the selectivity of the thiol-ene reactions allow for
easy modification of surface residues of BSA. Due to the high affinity between the N-terminus of
albumins and Cu(II), traditional CuAAC cannot be used. A strained cyclooctyne further modified
by an electron-withdrawing group provides an even easier and simpler alternative.
A NP that can successfully harness the advantages of albumin, avoid the pitfalls
encountered in other production methods, and gain the advantages of PEGylation with simple
surface modifications would prove beneficial for the advancement of nanotechnology as DDSs.

CHAPTER II
STATEMENT OF RESEARCH
The aim of this research is to develop a multi-use albumin-based nanoparticle for drug delivery
in order to address the concerns associated with current methodologies and available products.
The most pressing concerns are the cost and risk of pathogens associated with human-sourced
blood proteins, the negative effect on osmotic pressure due to a large dose of albumins, the
potential immune response and loss of biological activity due to heavy modification of these
albumins, and the need for organic solvents for preparation of these products.
Most market available albumin formulations use human serum albumin. When sourced
from blood donations, supplies are limited and the risk of potential contamination with pathogens
such as human immunodeficiency virus and hepatitis must be considered. Recombinant albumin
provides a reliable but expensive way to avoid these human pathogens. An alternative approach
is to use bovine serum albumin (BSA). This species of albumin is cheaper and more readily
available than its human counterpart. The two are structurally similar. Specifically, key residues
of Drug Sites 1 and 2 are conserved, suggesting similar binding capabilities.
Covalent attachment of polyethylene glycol (PEG) chains to proteins has been shown to
greatly increase circulatory half-life and reduce immunogenic response. In this research, several
BSAs will be attached to an 8-arm polyethylene glycol backbone (BSAx-R-PEG8) using two
types of reactions, resulting in different “R” group linkers between protein and backbone. Use of
a branched PEG backbone minimizes the effect on osmotic pressure. Upon administration of a
32
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single dose of drug, the total number of albumins introduced into the bloodstream will be greatly
reduced with BSAx-R-PEG8 as opposed to conventional albumin nanoparticles.
In the first part of this work, the lone, unpaired sulfhydryl of BSA at Cys34 will be
reacted with a maleimido-functionalized PEG8 (Mal-PEG8) resulting in a thioether (te) linkage.
This eliminates the need for organic solvents entirely, requires no additional modifications to the
protein and provides a chemoselective conjugation method. Yields, secondary structure,
speciation, and ligand binding capabilities will be determined for this form of PEGylated BSA
(BSAx-te-PEG8).
Secondly, BSAx-R-PEG8 will be prepared using strain-promoted azide-alkyne
cycloaddition. BSA, “activated” at a single superficial lysine with either a short- or long-chain
Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-NHS; DIBO-PEG4-NHS), will be
PEGylated via reaction with complimentary terminal azides (N3-PEG8). BSA and PEG8 will be
conjugated via a 1,2,3-triazole (123t). This approach requires a single modification of the
albumin and a minimal amount of organic solvent necessary to dissolve each activating agent.
PEGylated BSA activated with the short alkyne (BSAx-123t-PEG8) will be used to optimize the
PEGylation methodology. BSAx-123t-PEG8 and PEGylated BSA activated with the longer
alkyne (BSAx-PEG4-123t-PEG8) will be characterized in terms of secondary structure,
speciation, and ligand-binding capabilities.
The third area of research examines the effect of these methods of PEGylation on the
stability of BSA. Monitoring the temperatures of denaturation and aggregation of PEGylated
BSA has shown a reduction in thermal stability of the attached protein. Published works have
examined complexes containing a single albumin conjugated with multiple PEG backbones,
resulting in a higher degree of modification. These complexes showed a slight decrease in the
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temperature of denaturation is accompanied by an increase in the temperature of aggregation.
BSAx-te-PEG8, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 complexes require a single point
of modification in order to attach multiple albumins to a single PEG backbone. Less
modification of albumin may have less effect on the thermal stability of the final product.
Traditional pasteurization of albumin requires N-acetyl-L-tryptophan and sodium
caprylate to stabilize the protein during the heating process. Both of these additives have shown a
preference for DS2, creating competition for potential ligands. In an effort to eliminate these
stabilizers, PEGylated BSA will be pasteurized in the absence of both reagents. The effects of
pasteurization on the helicity and ligand binding capabilities of PEGylation by both thiolmaleimide and strain-promoted azide-alkyne cycloaddition reactions in conjunction with the preloading of a DS2 ligand will be monitored.
Every drug delivery system must be non-toxic, non-immunogenic, cost-effective, easy to
produce, and applicable to a variety of ligands. By addressing the concerns associated with
previous approaches, these qualities can be achieved.

CHAPTER III
MODIFICATION OF BOVINE SERUM ALBUMIN WITH
MAL-PEG8 AS A DRUG DELIVERY SYSTEM
Introduction
Serum albumin has become an attractive option in the development of drug delivery systems
largely due to its role as a vehicle for hydrophobic molecules. Human serum albumin (HSA) has
been studied extensively for this purpose but the cost of production and risk of pathogenic
transfer are considerable. Bovine serum albumin (BSA) provides a more cost-effective and
readily available alternative while maintaining key structural features, including two drug
binding sites, DS1 and DS2.
Crystallographic data has shown that DS1 and DS2 are well-conserved between HSA and
BSA (Bujacz, Zielinski & Sekula, 2014; Lejon, Cramer & Nordberg, 2008). The polar
environment at the mouth of DS1 is the sole difference between binding sites of these species. In
HSA, the polar cluster consists of residues K195, K199, R218, and R222 while in BSA, the
entrance is coated in mostly arginines (R194, R198, R217, and K221). Arginine, while still
capable of hydrogen-bonding, has a more dispersed positive charge and a larger functional
group. Sterics as well as the delocalization of the positive charge weaken interactions with
individual polar molecules (Li, Vorobyov & Allen, 2013). Despite this difference, it is believed
that DS1 and DS2 on BSA will house similar molecules as HSA.
A single, free cysteine at position 34 is also conserved across species. In the body, Cys34
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plays a key role as an antioxidant (Anraku, Chuang, Maruyama & Otagiri, 2013; Roche,
Rondeau, Singh, Tarnus & Bourdon, 2008) and is also capable of binding various ligands
(LeBlanc, Shiao, Roy & Sleno, 2014; Narazaki, Hamada, Harada & Otagiri, 1996; Noort, Hulst
& Jansen, 2002). In terms of drug delivery system development, the most attractive aspect of
Cys34 is that it provides an accessible, chemoselective site for surface modification.
Cysteine has been selectively modified using a variety of chemistries (Abbas, Xing &
Loh, 2014; Abegg et al., 2015; Mehtala, Kulczar, Lavan, Knipp & Wei, 2015) in order to
increase the circulatory half-lives of a variety of protein-based therapies (Léger et al., 2004;
Plesner, Fee, Westh & Nielsen, 2011; Stoddart et al., 2008). CJC-1134-PC is an application of
ConjuChem’s Preformed Conjugate-Drug Affinity Complex (PC-DACTM) technology for the
treatment of type 2 diabetes. This complex consists of maleimido-functionalized Exendin-4, a
homolog of glucagon-like peptide 1, covalently attached to recombinant human albumin via
interaction with Cys34. Exendin-4 has a short half-life, requiring twice daily injections to
maintain therapeutic levels. Conjugation onto albumin extends circulatory lifetime while
maintaining biological potency (Baggio, Huang, Cao & Drucker, 2008).
In the case of PC-DAC, the therapeutic agent is left exposed to the environment in order
to interact with cell surface targets. However, drug molecules need to be removed from the
environment. Direct conjugation of a drug to Cys34 provides no protection for the ligand,
subjecting the bound drug to possible degradation or alteration. The binding pockets of albumin
provide shelter for these molecules while keeping Cys34 free for surface modifications.
Cys34 is found in a shallow cleft at the surface of albumin in Domain IA (Figure 11).
DS2, found entirely in Domain IIIA, is likely unaffected by conjugation at a single residue in
Domain I. DS1, however, is found at the interface of Domains IB and IIA. Modification at Cys34
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may cause conformational changes which may alter the binding characteristics of DS1.

Figure 11. Cys34, Drug Site I, and Drug Site II of bovine serum albumin. (a) Cys34 (brown) is
located in Domain I (blue), adjacent to DS1 (pink) in Domain II (yellow). DS2 (green) in
Domain III (red) is far removed from Cys34. (b) It is slightly buried in a shallow cleft on the
surface of the protein. PDB ID: 4OR0 (Bujacz et al., 2014). All crystal structure images were
prepared using UCSF Chimera (Pettersen et al., 2004) and rendered with POV-Ray ("Persistence
of Vision Pty. Ltd.: Persistence of Vision (TM) Raytracer," 2004).
A common modification for protein-based drug delivery systems is covalent attachment
of a polyethylene glycol (PEG) backbone. PEG-protein conjugates often consist of multiple PEG
chains covalently attached at several locations on the surface of a single protein core (Nischan &
Hackenberger, 2014; Veronese & Pasut, 2005). This approach results in a potential problem for
albumin-based drug delivery systems. Albumin is a key regulator in osmotic pressure.
Administration of a large dose of individually PEGylated albumins may lead to down-regulation
of albumin production (Pietrangelo, Panduro, Chowdhury & Shafritz, 1992). Down-regulation
would result in accumulation of materials normally transported by albumin, such as toxic
metabolites and heavy metals.
A multi-albumin complex would allow for a higher drug dose with introduction of fewer
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albumins (Figure 12). Osmotic pressure is controlled by the number of particles, not their
individual sizes. In the case of serum proteins, with a MW of 400 kDa, fibrinogen is among the
largest but accounts for only 1% of total osmotic pressure due to low concentration (0.0075
mM). Albumin, however, is several times smaller (MW 66 kDa) but is found at a much higher
concentration (0.68 mM) and accounts for 79% of total osmotic pressure (Guyton & Hall, 2006).
For example, the same therapeutic dose of eight individual albumins pre-loaded with a drug
could be achieved with administration of a single eight-albumin particle, lessening the effects on
osmotic pressure of treatment.

Figure 12. Diagram of BSAx-te-PEG8. Thioether (te) linkages connect eight BSA molecules to a
single PEG8 backbone via reaction between terminal maleimides and native Cys34 residues.
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In this study, BSA will be attached to maleimido-functionalized PEG8 (Mal-PEG8) via
thiol-ene reaction (Figure 13). A thioether (te) linkage will connect BSA to the PEG8 backbone
via reaction between a terminal maleimide and native Cys34. The resulting BSAx-te-PEG8
(Figure 12) will be characterized in terms of yield, secondary structure, speciation, and ligand
binding.

Figure 13. Thiol-maleimide conjugation of bovine serum albumin onto PEG8. The free thiol of
Cys34 reacts with Mal-PEG8 to give a thioether linkage between protein and PEG backbone.
Materials and Methods
Materials
Lyophilized BSA (Product Number A7906), sulfamethoxazole (SMZ; S7507), naproxen
(NPX; N8280), and all reagents not detailed were purchased from Sigma-Aldrich.
Methods
All experiments were carried out in 50 mM 4-Morpholinepropanesulfonic acid/0.15 M
NaCl pH 7.2 (MOPS/NaCl) buffer unless otherwise noted. Fast protein liquid chromatography
(FPLC) separations were performed on an ÄKTAprime plus chromatography system (Amersham
Biosciences; 11001313) with MOPS/NaCl mobile phase. Resulting fractions were concentrated
with 30 kDa MW cut-off centrifuge filters (Sartorius; VS2022). BSA concentrations were
calculated using absorbance values obtained on an Agilent 8453 UV-visible Spectroscopy
System at 280 nm with an extinction coefficient of 43.824 mM-1 cm-1 and a MW of 66,430 Da
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(Hirayama, Akashi, Furuya & Fukuhara, 1990; "Thermo Scientific: Extinction Coefficients,"
2013).
Fatty acid removal. Fatty acid-free BSA (FAF-BSA) was prepared via an activated
charcoal method (Chen, 1967). In short, BSA was dissolved in MOPS/NaCl. The solution was
acidified to pH 3 and stirred on ice with 20-40 mesh particle size activated charcoal in order to
remove any bound fatty acids. Charcoal was pelleted at 10,000 rpm and the supernatant was
filtered through 0.2 µm cellulose filters to remove any remaining carbon. The de-fatted albumin
solution was returned to pH 7.2 before further purification. Dimers were removed by size
exclusion chromatography (SEC) on a pre-packed 120 mL 60 cm x 16 mm S300 FPLC column
(GE Healthcare; 17-1167-01).
PEGylation of FAF-BSA. The final product consisted of multiple BSA molecules
attached to a PEG8 backbone via a thioether (te) linkage formed by the reaction of terminal
maleimides of PEG8 and the sulfhydryl of Cys34 (BSAx-te-PEG8). 40 kDa Mal-PEG8 (Creative
PEGworks; PSB-864) was dissolved in MOPS/NaCl and added to 1 mM FAF-BSA at 8:1 FAFBSA:Mal-PEG8. The solution was allowed to incubate at room temperature for one week with
constant stirring. PEGylated FAF-BSA was purified via a two-phase SEC separation. The bulk
of unreacted FAF-BSA was removed by way of an S300 FPLC column, the remainder via a 320
mL 60 cm x 26 mm S500 column (GE Healthcare; 28-9356-07). Chromatograms from the S300
separation were processed in PrimeView 5.0 software to determine yields as the percentage of
total area count.
Circular dichroism (CD). The effects on secondary structure of the PEGylation
procedure were determined by CD. BSAx-te-PEG8 were assayed in 50 mM MOPS pH 7.2.
Studies were done on an Olis DSM 20 CD Spectrophotometer. Spectra were collected at 30oC
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over the range of 190-260 nm with a step-size of 1 nm. Helicity was calculated with DichroWeb
(Whitmore & Wallace, 2008) and the analysis program CDSSTR (Sreerama & Woody, 2000).
Inclusion of a crystal structure for HSA (Wardell et al., 2002) allowed for use of reference set
SP175 (Janes, 2009; Lees, Miles, Wien & Wallace, 2006).
SDS-PAGE. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
was performed as an initial characterization of BSAx-te-PEG8 species. The assay was performed
on a PhastSystem (Amersham Biosciences; 18-1018-23) with a 4-15% gradient PhastGel (GE
Healthcare; 17-0678-01), Coomassie R 350 stain (GE Healthcare; 17-0518-01), and high
molecular weight markers (GE Healthcare; 17-0615-01).
Analytical ultracentrifugation (AUC). AUC was carried out in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge using standard two sector cells with quartz
windows in four- or eight-hole rotors. All sedimentation velocity experiments were performed at
50,000 rpm with a preset scan number of 100 per cell. The reference sector was filled with 450
µL of MOPS/NaCl and the sample sector was filled with 430 µL of sample with an absorbance at
280 nm between 0.75 and 1.1. Path length was 1 cm. Buffer density was measured at 20.0oC in a
Mettler/Paar Calculating Density Meter DMA 55A and the buffer viscosity was measured in an
Anton Parr AMVn Automated Microviscometer. Data were analyzed using the program Sedfit
(Schuck, 2000; "Sedfit," 2017). Molecular weights and sedimentation coefficients (S20,w) were
determined using the continuous c(s) mode in the Sedfit program. Native monomeric BSA
yielded an S20,w value of 4.04 S which agreed with published values (Shulman, 1953; Taylor,
1952; Zhao et al., 2015). The c(s) plots were deconvoluted using non-linear least-squares fitting
algorithms available in the Origin (v. 9.0) software package (OriginLab Corporation,
Northampton, MA). Data were fit to multiple Gaussian components, increasing the number of
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components until residual plots (data-fit) were random and the chi square value for the fit was
minimal. Values reported are percentages of the total area count of peaks corresponding to
PEGylated species. These area counts were calculated via the trapezoidal formula.
Fluorimetric analyses. Binding studies were performed on a Photon Technology
International fluorimeter using Felix software (version 1.1). SMZ, a DS1 ligand, and NPX, a
DS2 ligand, were studied to determine if PEGylation affected ligand binding capabilities. The
number of binding sites (n) and the association constant (Ka) were calculated for BSAx-te-PEG8.
In each case, the fluorophore monitored was Trp213, found at the entrance to DS1 in Domain
IIA.
For SMZ, 30 µM stock solutions of FAF-BSA and BSAx-te-PEG8 were prepared in 0.2
M Tris-HCl/0.1 M NaCl pH 7.4. SMZ was dissolved in methanol to a final stock concentration
of 30 mM. Working SMZ stocks were prepared at 3 mM and 1 mM by dilution with Tris buffer.
Monitoring emission between 300-380 nm upon excitation at 283 nm at 25oC, aliquots of
working SMZ stocks were titrated into a 3 µM BSA solution. 1 mM working stock was used up
to 20 µM SMZ. 3 mM working stock was used to raise the final concentration to 80 µM SMZ.
To determine n and Ka for NPX, 30 µM stock solutions of FAF-BSA and BSAx-te-PEG8
were prepared in 10 mM phosphate buffer pH 7.0. NPX was dissolved in methanol to a final
stock concentration of 45 mM. A working NPX stock was prepared at 0.15 mM by dilution with
phosphate buffer. Monitoring emission between 300-380 nm upon excitation at 295 nm at 25oC,
aliquots of working NPX stocks were titrated into a 0.725 µM BSA solution to a final
concentration of 3 µM NPX.
Blanks for each ligand at each concentration were necessary to account for any
fluorescence due to the ligand itself. SMZ had almost no signal under experimental conditions.
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NPX, however, showed strong emission with maxima at approximately 350 nm. Particularly at
high concentrations, NPX signal obscured the BSA maxima which ranged from 344 to 350 nm.
Non-linear regression analyses were carried out using The Gnumeric Spreadsheet
(version 1.10.16) ("The Gnome Project: The Gnumeric Spreadsheet: Free, Fast, Accurate - pick
any three," 2011) and a modified Hill equation. In order to normalize samples, fractional
intensities (FrInt) were used in place of raw intensities.
FrInt =

FrInt ()* – FrInt (,- ∗ Ligand
K -5 + Ligand -

FrInt =

(Int , 89 :,;)-5 − Int = 89 :,;)-5 )
(Int ()* 89 :,;)-5 − Int = 89 :,;)-5 )
K) =

-

+ FrInt (,-

1
K5

Results and Discussion
BSAx-te-PEG8 Yield
BSAx-te-PEG8 was purified via two size exclusion FPLC columns (Figure 14).
Integration of the S300 separation showed that the PEGylation procedure converted an average
of 36.1 ± 0.6% of BSA into BSAx-te-PEG8. In the initial purification, a small peak eluted at
approximately 40 mL suggests the presence of extremely high molecular weight material. This
same material was buried in the S500 separation, resulting in peak broadening for BSAx-te-PEG8
fractions.
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Figure 14. Purification of thiol-maleimide PEGylated bovine serum albumin via size exclusion chromatography. (a) Initial purification
was done on an S300. (b) Final purification was done an S500 column. FAF-BSA (---) and BSAx-te-PEG8 (red).
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Effects on Secondary Structure
Helicity was maintained after the PEGylation procedure. BSAx-te-PEG8 contained
minima at 210 nm and 220 nm which are characteristic of α-helices (Figure 15). The secondary
structure of FAF-BSA was 59.2 ± 2.2% α-helical. PEGylation resulted in a slight decrease in
helicity to 56.3 ± 1.3%. Both values are in agreement with published values which range from
56-66% helical content for BSA (Das et al., 2017; Moriyama et al., 2008). Given that Cys34 is
shallowly sheltered in a cleft between two helices, attachment of a large PEG chain may have
caused some loss of helicity.
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Figure 15. Circular dichroic spectra of FAF-BSA and BSAx-te-PEG8. FAF-BSA (---) and
BSAx-te-PEG8 (red) contain minima at 210 nm and 220 nm characteristic of α-helices.
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BSAx-te-PEG8 Speciation
Electrophoretic separation of PEGylated BSA via SDS-PAGE revealed the presence of
high molecular weight material (Figure 16). A faint band at 116 kDa corresponds to dimeric
BSA and BSA1-te-PEG8 (MW 106 kDa). A second faint band at 170 kDa corresponds to BSA2te-PEG8 (MW 172 kDa). A dark streak at MWs heavier than 220 kDa contains distinct banding,
most likely corresponding to BSA3-4-te-PEG8. Material retained in the stacking zone is made of
five or more PEGylated BSAs as the molecular weight cut-off for proteins in the separating zone
is 300 kDa. Smearing is most likely due to interaction of the PEG8 backbone with the
polyacrylamide gel.

Figure 16. Electrophoretic separation of species of bovine serum albumin PEGylated via thiolmaleimide click chemistry. Lane 1-2: BSAx-te-PEG8; Lane 3: FAF-BSA; Lane 4: High
molecular weight marker.
Several species of PEGylated BSA were found via AUC (Figure 17). 70% of the total
PEGylated area count was due to BSA2-6-te-PEG8. 11% corresponded to a single BSA attached
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to a single PEG8 backbone. The remaining 19% consisted of very high molecular weight species.
Given that there are only eight arms on Mal-PEG8 and only one free cysteine on BSA, the largest
particle, BSA8-te-PEG8, would have a MW of 502 kDa. Peaks with a sedimentation coefficient
greater than 15 S have calculated molecular weights well above this mark. It is believed that the
extremely high molecular weight species are a combination of BSA7-8-te-PEG8 and PEGylated
species of a side-reaction of Mal-PEG8.
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Figure 17. Analytical ultracentrifugation analysis of BSAx-te-PEG8. % Area Count values are the
percent of PEGylated species only. nr: not reported; n/a: not applicable.
Maleimides react readily with sulfhydryls, however, Mal groups may also react with the
terminal amino group of lysine (Brewer & Riehm, 1967). At neutral pH, thiolation occurs 1000
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times faster than the lysine interaction. Given the high concentration of the reaction mixture, the
large number of superficial lysines, and the long incubation time, it is highly possible that
multiple lysines reacted with one or more PEG8 chains to create very high molecular weight
oligomers.
Results were similar to hemoglobin-based nanoparticles developed with the same MalPEG8 (K. D. Webster et al., 2017). Hemoglobin, a 64 kDa tetrameric protein, contains two free
cysteines at position 93 of each β-subunit. Similar reaction conditions to those used in this study
resulted in a heterogeneous mixture of PEG8 complexed with predominantly three hemoglobins.
As many as six hemoglobin tetramers were found to be conjugated to a single PEG8 backbone.
BSA, similar in size to hemoglobin, behaved in a similar fashion during PEGylation. A similar
spread of conjugated protein was found, with a majority of PEGylated species falling between
two and six BSA molecules per PEG8 backbone.
Ligand Binding Capabilities
Fluorescent emission was monitored to determine the viability of DS1 and DS2 of PEGconjugated BSA. NPX was used to probe DS2. Published crystal structures of de-fatted bovine,
equine, and leporine serum albumins complexed with NPX indicate a preference for DS2
(Bujacz et al., 2014). Experimental values for NPX in the presence of FAF-BSA and BSAx-tePEG8 were consistent with published values (Table 4), suggesting that DS2 remains intact upon
PEGylation. While the crystal structure reported by Bujacz et al. show three NPX molecules
bound, DS2 has been the only high affinity site reported. Discrepancies in the n values are
possibly due to de-fatted BSA used in this work while fatty acid-containing albumin was used in
the published results.
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Table 4. Association Constants (Ka) and Number of Binding Sites (n) for BSAx-te-PEG8 for
Sulfamethoxazole and Naproxen.
SMZ
3

-1

NPX
7

-1

Sample

Ka (x10 M )

n

Ka (x10 M )

n

FAF-BSA
BSAx-te-PEG8

2.03 ± 0.18
0.19 ± 0.05

0.9 ± 0.1
0.8 ± 0.03

0.40 ± 0.13
1.99 ± 0.17

0.4 ± 0.1
0.9 ± 0.3

3.55-15.6

0.9-1.0

0.12-3.70

0.6-3

Lit. values1,2
1

SMZ values were published by Naik et al. (2009; 2015), Rajendiran & Thulasidhasan (2015), and Wang et al.
(2014).
2

NPX values were reported by Banerjee et al. (2006), Bou-Abdallah et al. (2016), Fielding et al. (2005), and Honoré
& Brodersen (1984). Bujacz et al. (2014) have reported a crystal structure (PDB ID: 4OR0) for BSA complexed
with three NPX molecules.

Binding of NPX to FAF-BSA and BSAx-te-PEG8 showed similar trends (Figure 18).
BSA in the absence of NPX had a maximum emission wavelength at 344 nm. With increasing
amounts of NPX, a red shift resulted in a maximum at 350 nm. This is consistent with binding to
a site adjacent to the fluorophore. In this case, the fluorophore studied was Trp213 found in
Domain IIA at the mouth of DS1. As ligand binds to DS2, slight conformational changes
exposed Trp213 to the solvent, causing a red shift.
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Figure 18. Fluorimetric spectra and non-linear regression of BSAx-te-PEG8 in the presence of
naproxen. (a) BSAx-te-PEG8 and (b) FAF-BSA spectra. BSA in the absence of NPX (---) had a
maximum emission at 344 nm. Upon addition of NPX to a final concentration of 3 µM,
maximum emission shifted to 350 nm and intensities increased. (c) Non-linear regression
analyses for BSAx-te-PEG8 (red £) and FAF-BSA (black ¯). Experimental data is represented
as symbols while calculated data points are lines of the same color.
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DS1, however, appears to be greatly affected by the covalent modification of Cys34.
FAF-BSA values were similar to published values for both Ka and n for SMZ studies (Table 4).
However, BSAx-te-PEG8 demonstrated a greatly reduced affinity for SMZ. Spectra for both
FAF-BSA and BSAx-te-PEG8 followed similar trends (Figure 19). Intensities decreased as SMZ
concentration increased. The signal from Trp213 is quenched in the presence of the ligand
though it is not tightly bound in BSAx-te-PEG8. Modification of Cys34 in Domain IA, clearly
had an effect on binding to DS1 in Domains IB and IIA.
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Figure 19. Fluorimetric spectra and non-linear regression of BSAx-te-PEG8 in the presence of
sulfamethoxazole. (a) BSAx-te-PEG8 and (b) FAF-BSA spectra. BSA in the absence of
SMZ (---) had a maximum emission at 346 nm. Intensities decreased with each addition of SMZ.
(c) Non-linear regression analyses for BSAx-te-PEG8 (red £) and FAF-BSA (black ¯).
Experimental data is represented as symbols while calculated data points are lines following the
same color.
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Conclusions
Mal-PEG8 was successfully used as a scaffolding to combine multiple native BSA
molecules into a single complex with drug binding capabilities. The reaction was simple to run,
requiring only a relatively high molar ratio of FAF-BSA:Mal-PEG8. A majority of PEGylated
species contained 2-6 BSA molecules though some species of molecular weights greater than
BSA8-te-PEG8 were found. While a larger spread of BSAx-te-PEG8 species were generated, the
complexes still showed the ability to effectively bind drugs to DS2, maintaining the key
functionality of these albumin-based nanoparticles.

CHAPTER IV
CONJUGATION OF BOVINE SERUM ALBUMIN ONTO PEG8 VIA
STRAIN-PROMOTED AZIDE-ALKYNE CYCLOADDITION
AS A DRUG DELIVERY SYSTEM
Introduction
The hydrophobicity of many drugs is a major hurdle for efficient delivery to target tissues. Drug
delivery systems (DDS) aim to increase the bioavailability of pharmaceuticals by increasing the
solubility and subsequently their efficacy. Increased solubility also reduces the risk of rapid
elimination and in vivo degradation.
The ideal DDS must be non-immunogenic, easily eliminated, and applicable to a range of
drugs. This versatility requires the ability to bind different types of ligands and allow for
targeting of specific cell types. It must protect the ligand from degradation while protecting the
host from toxicity by chaperoning bound drug to the site of action.
Incorporation of serum albumin into a DDS would address many of these points.
Albumin serves as a natural vehicle for insoluble materials by binding these molecules in a
variety of hydrophobic pockets found throughout its structure. Albumin-based DDSs have also
been shown to greatly increase the aqueous solubility of drugs (Khoder et al., 2016). By
sequestering a pharmaceutical, albumin provides protection against degradation, redox reactions,
and immunogenic agents. Additionally, the drug is no longer available to freely move through
the bloodstream and possibly damage healthy tissue, protecting the patient.
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These hydrophobic cavities are able to non-covalently bind a wide variety of ligands,
making albumin a versatile drug carrier. Fatty acids (Bhattacharya, Grüne & Curry, 2000), heavy
metals (Bal, Christodoulou, Sadler & Tucker, 1998; Rózga, Sokołowska, Protas & Bal, 2007),
and metabolites such as bilirubin (Zunszain, Ghuman, McDonagh & Curry, 2008) are just a few
of the endogenous materials transported by albumin. The two main binding sites of extrinsic
hydrophobic molecules are Drug Site I (DS1) and Drug Site II (DS2). Both are mostly apolar
pockets with only a few hydrophilic residues. DS1, located at the interface between Domains IB
and IIA, is a large, multi-chambered cavity which is able to accommodate multiple ligands of
different sizes. DS2, found entirely in Domain IIIA, is less versatile and shows a higher degree
of stereospecificity due to a much more compact structure. These binding sites are reviewed in
greater detail by Ghuman et al. (2005) and Yamasaki et al. (2013).
Albumin also allows for specific cell targeting. Tumor cells have been shown to
accumulate albumins passively through the enhanced permeation and retention effect and
actively via albondin-mediated transcytosis (Desai, 2008; Hawkins, Soon-Shiong & Desai, 2008;
Tiruppathi, Song, Bergenfeldt, Sass & Malik, 1997). This provides a natural targeting ability for
chemotherapeutics and led to the approval of Abraxane®, an albumin-based DDS of paclitaxel
for treatment of metastatic breast cancer (Desai, 2008).
Additionally, albumins contain up to 59 lysine residues. The terminal amino groups of
these residues provide a potential site for surface modification with antibodies (Anhorn, Wagner,
Kreuter, Langer & von Briesen, 2008), vitamins (Leamon & Low, 1991), and other targeting
molecules.
One concern for using albumin as a drug-carrier is the effect on osmotic pressure upon
introduction of a large number of free, individual albumins. Approximately 79% of osmotic
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pressure is credited to albumin (Guyton & Hall, 2006). For this reason, serum albumin levels are
tightly regulated by the body. A large infusion of free albumin would be accompanied by downregulation of albumin production (Pietrangelo, Panduro, Chowdhury & Shafritz, 1992). This
would lead to aggregation of fatty acids and other endogenous, insoluble biomaterials in blood
and tissue.
Conjugation of multiple bovine serum albumin (BSA) molecules onto a single eightarmed polyethylene glycol backbone (BSAx-R-123t-PEG8) addresses this concern (Figure 20).
The linker between PEG8 and BSA in this diagram is a 1,2,3-triazole (123t) formed by strainpromoted azide-alkyne cycloaddition (SPAAC) with a variable R group spacer between protein
and alkyne. Osmotic pressure is dependent on the number of molecules present, not their
individual masses. Delivering the same dose of albumin-drug via BSAx-R-123t-PEG8 would
have less effect on the osmotic pressure. For example, to deliver therapeutic levels of drug, PEG8
complexed with eight BSA molecules would require one-eighth of the dose of unmodified
albumin. Osmotic pressure would be affected by a single molecule as opposed to eight.
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Figure 20. Diagram of BSAx-R-123t-PEG8. PEGylation run to completion would result in eight
BSAs attached to a single PEG8 backbone. The linkers between PEG8 and BSA are a 1,2,3triazole (123t) formed by SPAAC with a variable R group spacer between protein and alkyne.
PEG is a biologically inert polymer commercially available in a wide variety of sizes and
functional groups ("Creative PEGworks: PEG Products," 2017; "JenKem Technology: PEG
Products," 2017). Inclusion of a PEG backbone into a DDS would increase solubility of the
complex and provide additional protection of the attached BSA molecules from degradation and
in vivo modifications.

59
Human serum albumin (HSA) has been the main albumin studied for delivery of
synthetic hydrophobic molecules. HSA, being a human-sourced, blood-borne protein, presents an
increased risk of pathogen transfer. Recombinant human albumins have been developed but are
expensive to produce (Bosse et al., 2005; He et al., 2011). BSA provides a readily available and
inexpensive alternative to its human counterpart. Crystallographic data has shown that many
structural features, including DS1 and DS2, are well-conserved between HSA and BSA (Bujacz,
Zielinski & Sekula, 2014; Lejon, Cramer & Nordberg, 2008). The polar environment at the
mouth of DS1 is the sole difference between binding sites of these species. In HSA, the polar
cluster consists of residues K195, K199, R218, and R222 while in BSA, the entrance is coated in
mostly arginines (R194, R198, R217, and K221). While still capable of hydrogen-bonding,
arginine has a more dispersed positive charge and a larger functional group. Sterics as well as the
delocalization of the positive charge weaken interactions with individual polar molecules (Li,
Vorobyov & Allen, 2013). Despite this difference, it is believed that DS1 and DS2 on BSA will
house similar molecules as HSA.
While BSA is a natural product that shares a large number of similarities with
endogenous HSA, BSA is still a foreign molecule and is at risk of being treated as such upon
administration to humans. Studies have shown that oral and parenteral administration of
unmodified BSA to humans resulted in production of BSA antibodies. In some cases, no immune
response was invoked (Korenblat, Rothberg, Minden & Farr, 1968). In cross-species
administration of proteins, covalently attached PEG has been shown to effectively mask the
foreign molecules and greatly reduce immunogenic response (Gefen et al., 2013). A PEGylated
complex such as BSAx-R-123t-PEG8 (Figure 20) may hide the foreign BSA molecules from
immunogenic agents.
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Studies have shown that PEGylated proteins are safely metabolized in two stages. First,
protein components are degraded. In the case of albumin, glycoproteins gp18 and gp30 bind to
albumin, tagging it for lysosomal catabolism (Larsen, Kuhlmann, Hvam & Howard, 2016;
Schnitzer, Sung, Horvat & Bravo, 1992; Stehle, Sinn, Wunder, Schrenk, Stewart et al., 1997).
The remaining PEG backbone is excreted through the kidneys (R. Webster et al., 2009). Safe
metabolism is key for any DDS. Once the drug has been delivered, deleterious effects of the
DDS or its metabolites are undesirable.
This BSAx-R-123t-PEG8 complex will be generated using “click” chemistry. The term
denotes reactions that are modular, able to give near quantitative yields, and are stereospecific.
These reactions are simple, easy to perform and insensitive to water and oxygen (Lowe, 2010).
SPAAC is a form of click chemistry in which a terminal azide is reacted with an alkyne
incorporated into a cyclooctyl or cyclononyl ring. To further strain the already reactive cyclic
structure, electron-withdrawing groups have been incorporated adjacent to the alkyne in order to
make it even more reactive with the complimentary azide. The most commonly utilized groups
are difluoro- and dibenzo- moieties (Ning, Guo, Wolfert & Boons, 2008; van Berkel et al.,
2007). SPAAC allows for a simple and straightforward production method which does not
require special equipment, high pressures, or elevated temperatures.
Additionally, SPAAC is a biorthogonal reaction which provides a stable, covalent linker
between protein and PEG. Neither alkyne nor azide are reactive with common functional groups
found in the body (Baskin & Bertozzi, 2009). This non-reactivity eliminates the possibility of
side-reactions between residual, unreacted SPAAC groups and native proteins upon
administration. The BSAx-R-123t-PEG8 complex will pass through a variety of environments as
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it circulates through the body. The stable 1,2,3-triazole linker will reduce the chances of
dissolution of the PEG complex before delivery of ligand (Massarotti et al., 2014).

Figure 21. Conjugation of bovine serum albumin onto PEG8 via strain-promoted azide-alkyne
cycloaddition. (a) BSA is first activated with DIBO-R-NHS at a single lysine. Activated BSA is
attached to the PEG8 backbone via SPAAC. “R” denotes a variable spacer incorporated into the
activating reagent. (b) DIBO-NHS and (c) DIBO-PEG4-NHS were used to activate BSA.
In this study, dibenzocyclooctyl-functionalized BSA molecules (DIBO-R-BSA) will be
conjugated onto an 8-arm PEG backbone functionalized with terminal azides (N3-PEG8) (Figure
21). BSA will be “activated” with one of two N-hydroxysuccinimidyl ester-functionalized DIBO
reagents (DIBO-R-NHS) via one of BSA’s 59 native lysine residues (Cline & Hanna, 1988).
A short activator, Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-NHS), was
used from the outset of this study. In an attempt to increase yields, the longer
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Dibenzocyclooctyne-PEG4-N-hydroxysuccinimidyl ester (DIBO-PEG4-NHS) was added. It was
hypothesized that once a few BSA molecules attached to the backbone, additional proteins would
be unable to access the remaining PEG arms due to steric hindrance. The PEG4 spacer provided
an additional 14 Å between protein and alkyne. The reduced congestion at the attachment sites
between DIBO and N3 was expected to increase yields. Also, with easier access to the PEG
backbone, heterogeneity of the product was expected to decrease, resulting in fewer species of
BSAx-R-123t-PEG8.
A 1:1 activation ratio of DIBO:BSA will be used and the PEGylation methodology will
be optimized to give the highest yield of PEGylated protein. The degree of activation will also be
determined using Fluorescein-NHS (Fluor-NHS) to mimic the interaction of BSA and the
activating agents. The PEGylated complexes will then be characterized in terms of secondary
structure, speciation, and ligand-binding capabilities.
Materials and Methods
Materials
Lyophilized BSA (Product Number A7906), DIBO-NHS (761524), DIBO-PEG4-NHS
(764019), Fluorescein-5-EX N-hydroxysuccinimide ester (Fluor-NHS; F9551), sulfamethoxazole
(SMZ; S7507), naproxen (NPX; N8280), and all reagents not detailed were purchased from
Sigma-Aldrich.
Methods
All experiments were carried out in 50 mM 4-Morpholinepropanesulfonic acid/0.15 M
NaCl pH 7.2 (MOPS/NaCl) buffer unless otherwise noted. Fast protein liquid chromatography
(FPLC) separations were performed on an ÄKTAprime plus chromatography system (Amersham
Biosciences; 11001313) with MOPS/NaCl mobile phase. Resulting fractions were concentrated
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with 30 kDa MW cut-off centrifuge filters (Sartorius; VS2022). Absorbance values were
obtained on an Agilent 8453 UV-visible Spectroscopy System. BSA concentrations were
calculated at 280 nm with an extinction coefficient of 43.824 mM-1 cm-1 and a MW of 66,430 Da
(Hirayama, Akashi, Furuya & Fukuhara, 1990; "Thermo Scientific: Extinction Coefficients,"
2013).
Fatty acid removal. Fatty acid-free BSA (FAF-BSA) was prepared via an activated
charcoal method (Chen, 1967). In short, BSA was dissolved in MOPS/NaCl. The solution was
acidified to pH 3 and stirred on ice with 20-40 mesh particle size activated charcoal in order to
remove any bound fatty acids. Charcoal was pelleted at 10,000 rpm and the supernatant was
filtered through 0.2 µm cellulose filters to remove any remaining carbon. The de-fatted albumin
solution was returned to pH 7.2 before further purification. Dimers were removed by size
exclusion chromatography (SEC) on a pre-packed 120 mL 60 cm x 16 mm S300 FPLC column
(GE Healthcare; 17-1167-01).
Activation of FAF-BSA with DIBO. Conjugation of BSA molecules onto a 40 kDa N3PEG8 backbone required two steps, activation and PEGylation (Figure 21). Table 5 details the
nomenclature used to discuss these reactions.
Table 5. Nomenclature for the Conjugation of BSA onto PEG8 via Strain-Promoted AzideAlkyne Cycloaddition. Reaction with complimentary azide for all DIBO-functionalized BSA
reactions results in a 1,2,3-triazole (123t).
Activator
DIBO-R-NHS
(generic)
DIBO-NHS
(short)
DIBO-PEG4-NHS
(long)

Activated BSA

PEG Product

DIBO-R-BSA

BSAx-R-123t-PEG8

DIBO-BSA

BSAx-123t-PEG8

DIBO-PEG4-BSA

BSAx-PEG4-123t-PEG8
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Activation involves the attachment of a DIBO functional group onto BSA via reaction
between an NHS-ester and the amino side-chain of lysine. DIBO-NHS and DIBO-PEG4-NHS
stocks were prepared in dry dimethyl sulfoxide and added to 1 mM FAF-BSA to give a final
ratio of 1:1 DIBO-R-NHS:FAF-BSA. Introduction of DIBO-R-NHS was made in small aliquots
with mixing between additions to avoid BSA denaturation due to the organic solvent. After two
hours at room temperature, excess activator was removed by triple-rinsing the sample through 30
kDa centrifuge filters ("Thermo Scientific: NHS-Azide and NHS-Phosphine Reagents," 2014).
PEGylation of DIBO-activated FAF-BSA. N3-PEG8 (Creative PEGworks; PSB-884)
was dissolved in MOPS/NaCl and added to 1 mM DIBO-activated FAF-BSA at 16:1 DIBO-RBSA:N3-PEG8. The solution was allowed to incubate at room temperature for one week with
constant stirring. PEGylated FAF-BSA was purified via a two-phase SEC separation. The bulk
of unreacted FAF-BSA was removed by way of an S300 FPLC column, the remainder via a 320
mL 60 cm x 26 mm S500 column (GE Healthcare; 28-9356-07). Chromatograms from the S300
separation were processed in PrimeView 5.0 software to determine yields as the percentage of
total area count.
PEGylation optimization. Optimization of the PEGylation methodology was determined
by monitoring the amount of BSAx-123t-PEG8 produced with varying PEGylation ratios,
temperatures, and incubation times. PEGylation ratios were monitored at 4, 8, 16, 32, and 128:1
DIBO-BSA:N3-PEG8. Reactions were carried out at 4oC, room temperature, and 32oC for one
week. The time trial was performed by determing the amount of product formed after two, five,
and seven days of incubation. Weekly assays were performed over the course of an additional
four weeks. The baseline conditions for all PEGylation reactions were 16:1 DIBO-BSA:N3-PEG8
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at room temperature for one week with constant stirring. Samples were passed through an S500
column and the amount of product was determined as the percentage of total area count.
Fluorescent labeling. The degree of activation was determined using Fluor-NHS to
mimic the DIBO activators. Fluor-NHS has a MW of 590.56 g/mol which is similar to both DIBONHS (MW 402.4) and DIBO-PEG4-NHS (MW 649.69). The activation procedure was followed,
substituting Fluor-NHS. Unreacted fluorophore was removed via triple rinse with 50 mM
Tricine/0.15 M NaCl pH 8.5 through 30 kDa centrifugation filters. The following calculations
used absorbance at 280 nm (λmax for BSA) and 495 nm (λmax for Flour) to determine
Fluorbound:FAF-BSA ("Thermo Scientific: NHS-Fluorescein," 2016).
Molar

Fluor
Abs/01 ∗ C
=
BSA
Abs456 − CF ∗ Abs/01

CF =

Abs456 of unreacted Fluor
Abs/01 of unreacted Fluor

6.E%
MW?@A Da ∗ E456
C =
MWGHIJK ∗ 195
6.E%
195 = E/01
of bound Fluor

MWFluor = 475.47 Da (MWFluor-NHS minus MWNHS which is lost upon
reaction with lysine)
Circular dichroism (CD). The effects on secondary structure of the PEGylation
procedure were determined by CD. BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8 were assayed
in 50 mM MOPS pH 7.2 at 30oC on an Olis DSM 20 CD Spectrophotometer. Ellipticity was
monitored between 190 nm and 260 nm. Helicity was calculated with DichroWeb (Whitmore &
Wallace, 2008) and the analysis program CDSSTR (Sreerama & Woody, 2000). Inclusion of a
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crystal structure for HSA (Wardell et al., 2002) allowed for use of reference set SP175 (Janes,
2009; Lees, Miles, Wien & Wallace, 2006).
SDS-PAGE. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
was performed as an initial characterization of BSAx-R-123t-PEG8 species. The assay was
performed on a PhastSystem (Amersham Biosciences; 18-1018-23) with a 4-15% gradient
PhastGel (GE Healthcare; 17-0678-01), Coomassie R 350 stain (GE Healthcare; 17-0518-01),
and high molecular weight markers (GE Healthcare; 17-0615-01).
Analytical ultracentrifugation (AUC). AUC was carried out in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge using standard two sector cells with quartz
windows in four- or eight-hole rotors. All sedimentation velocity experiments were performed at
50,000 rpm with a preset scan number of 100 per cell. The reference sector was filled with 450
µL of MOPS/NaCl and the sample sector was filled with 430 µL of sample with an absorbance at
280 nm between 0.75 and 1.1. Path length was 1 cm. Buffer density was measured at 20.0oC in a
Mettler/Paar Calculating Density Meter DMA 55A and the buffer viscosity was measured in an
Anton Parr AMVn Automated Microviscometer. Data were analyzed using the program Sedfit
(Schuck, 2000; "Sedfit," 2017). Molecular weights and sedimentation coefficients (S20,w) were
determined using the continuous c(s) mode in the Sedfit program. Native monomeric BSA
yielded an S20,w value of 4.04 S which agreed with published values (Shulman, 1953; Taylor,
1952; Zhao et al., 2015). The c(s) plots were deconvoluted using non-linear least-squares fitting
algorithms available in the Origin (v. 9.0) software package (OriginLab Corporation,
Northampton, MA). Data were fit to multiple Gaussian components, increasing the number of
components until residual plots (data-fit) were random and the chi square value for the fit was
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minimal. Values reported are percentages of the total area count of peaks corresponding to
PEGylated species. These area counts were calculated via the trapezoidal formula.
Fluorimetric analyses. Binding studies were performed on a Photon Technology
International fluorimeter using Felix software (version 1.1). SMZ, a DS1 ligand, and NPX, a
DS2 ligand, were studied to determine if PEGylation affected ligand binding capabilities. The
number of binding sites (n) and the association constant (Ka) were calculated for BSAx-123tPEG8 and BSAx-PEG4-123t-PEG8. In each case, the fluorophore monitored was Trp213, found at
the entrance to DS1 in Domain IIA.
For SMZ, 30 µM stock solutions of FAF-BSA, BSAx-123t-PEG8, and BSAx-PEG4-123tPEG8 were prepared in 0.2 M Tris-HCl/0.1 M NaCl pH 7.4. SMZ was dissolved in methanol to a
final stock concentration of 30 mM. Working SMZ stocks were prepared at 3 mM and 1 mM by
dilution with Tris buffer. Monitoring emission between 300-380 nm upon excitation at 283 nm at
25oC, aliquots of working SMZ stocks were titrated into a 3 µM BSA solution. 1 mM working
stock was used up to 20 µM SMZ. 3 mM working stock was used to raise the final concentration
to 80 µM SMZ.
To determine n and Ka for NPX, 30 µM stock solutions of FAF-BSA, BSAx-123t-PEG8,
and BSAx-PEG4-123t-PEG8 were prepared in 10 mM phosphate buffer pH 7.0. NPX was
dissolved in methanol to a final stock concentration of 45 mM. A working NPX stock was
prepared at 0.15 mM by dilution with phosphate buffer. Monitoring emission between 300-380
nm upon excitation at 295 nm at 25oC, aliquots of working NPX stocks were titrated into a 0.725
µM BSA solution to a final concentration of 3 µM NPX.
Blanks for each ligand at each concentration were necessary to account for any
fluorescence due to the ligand itself. SMZ had almost no signal under experimental conditions.
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NPX, however, showed strong emission with maxima at approximately 350 nm. Particularly at
high concentrations, NPX signal obscured the BSA maxima which ranges from 344 to 350 nm.
Non-linear regression analyses were carried out using The Gnumeric Spreadsheet
(version 1.10.16) ("The Gnome Project: The Gnumeric Spreadsheet: Free, Fast, Accurate - pick
any three," 2011) and a modified Hill equation. In order to normalize samples, fractional
intensities (FrInt) were used in place of raw intensities.
FrInt =

FrInt PQR – FrInt PTU ∗ Ligand
K UZ + Ligand U

FrInt =

(Int T ]^ _T`QUZ − Int 6 ]^ _T`QUZ )
(Int PQR ]^ _T`QUZ − Int 6 ]^ _T`QUZ )
KQ =

U

+ FrInt PTU

1
KZ

Results and Discussion
Methodology Optimization
The PEGylation portion of the polymerization procedure was optimized by varying the
PEGylation ratios, temperature, and reaction time. FAF-BSA was activated at a 1:1 mole ratio
with DIBO-NHS, triple-rinsed with MOPS/NaCl, and concentrated to 1 mM with 30 kDa
centrifuge filters before PEGylation. Samples were evaluated for BSAx-123t-PEG8 content as the
percent of the total area count after separation on an S500 column.
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Figure 22. Optimization of the PEGylation procedure for DIBO-activated FAF-BSA.
(a) PEGylation ratio and temperature were varied to produce the highest yields. (b) A time trial
of PEGylation at 1:1 activation with DIBO-NHS, 16:1 DIBO-BSA:N3-PEG8 at room
temperature.
PEGylation ratio proved to be the most effective control over product formation (Figure
22). Varying PEGylation ratios from 4:1 DIBO-BSA:N3-PEG8 to 128:1 showed a maximum of
31% BSAx-123t-PEG8 product formed at 16:1. When this ratio was pushed to a higher excess of
DIBO, the lowest yield of 4% was obtained at 128:1. This could be due to dilution of the N3PEG8, resulting in less interaction between azide and alkyne. When in excess of N3-PEG8, a
similarly low 9% is obtained. At 16:1, the optimal balance between DIBO-BSA:N3-PEG8 ratio
and individual reactant concentrations was found.
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Temperature proved to be the least effective control. Assays performed at room
temperature generated the highest yields. Slightly less product was formed at a lower
temperature (4oC) with similar results at an elevated temperature (37oC). The negligible
difference in yields suggests an indifference to temperature.
One week of reaction time was sufficient to generate a considerable amount of product.
Yields trended upwards over five weeks. While reacting for longer periods generated more
product, majority of the BSAx-123t-PEG8 was formed within the first seven days. Given an
already extensive reaction time, additional weeks of incubation were deemed unnecessary for
only slightly more product.
Effects on Secondary Structure
Helicity content for BSA has been reported between 56-66% (Das et al., 2017; Moriyama
et al., 2008). Characteristic minima at 210 nm and 220 nm were seen in all spectra of PEGylated
BSA (Figure 23). Unmodified FAF-BSA contained 59.2 ± 2.2% α-helix. Neither BSAx-123tPEG8 (63.4 ± 2.1%) nor BSAx-PEG4-123t-PEG8 (59.3 ± 3.5%) showed any loss in secondary
structure.

71
20
10
0
Ellipticity (millidegrees)

190

200

210

220

230

240

250

260

-10
-20
-30
-40
-50
-60
-70
-80

Wavelength (nm)

Figure 23. Circular dichroic spectra of FAF-BSA and strain-promoted azide-alkyne
cycloaddition PEGylated products. FAF-BSA (---); BSAx-123t-PEG8 (blue);
BSAx-PEG4-123t-PEG8 (orange).
Degree of Activation
A 1:1 activator:FAF-BSA mole ratio was necessary to reduce the risk of over-activation
resulting in a single BSA making multiple connections to a single or multiple N3-PEG8
backbones. The degree of activation was quantified using Fluor-NHS that would mimic the
interactions between FAF-BSA and either activating agent. By monitoring the absorbance
maxima at 280 nm and 495 nm, an average of 0.75 ± 0.04 Fluor per BSA was calculated. By
controlling the mole ratio of activator:FAF-BSA, the odds of multiple attachments was greatly
decreased.

72
BSAx-R-123t-PEG8 Yields
While the risk of over-PEGylation was limited, so too was the yield of PEGylated
protein. By integrating chromatograms from the S300 separation (Figure 24a), yields were
calculated for both DIBO reagents. The hypothesis that an additional 14 Å would be sufficient to
greatly increase yields was proven incorrect. The shorter DIBO-NHS produced an average of
23.6% BSAx-123t-PEG8 (range: 19.5-31.0%). The longer DIBO-PEG4-NHS generated only
slightly more product (average: 25.3%, range: 19.1-36.5%). The additional length of the
extended alkyne activating agent did not result in substantially higher yields but does suggest
that further separation of the bulky BSA from the bulky backbone of PEG8 may enhance yields.
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Figure 24. Purification of BSAx-R-123t-PEG8 via size exclusion chromatography. (a) Initial purification was done on an S300.
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BSAx-R-123t-PEG8 Speciation
Purified BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8 were run through an SDS-PAGE
4-15% gradient gel. A band at approximately 116 kDa corresponds to a combination of dimeric
BSA and BSA1-R-123t-PEG8 conjugates (Figure 25). High molecular weight bands in the
separation zone and a heavy band retained in the stacking zone were seen for both BSAx-123tPEG8 and BSAx-PEG4-123t-PEG8. This suggests a minimum of three to four species of
PEGylated FAF-BSA were formed with either activating agent. The bands likely correspond to
PEG8 +2 FAF-BSA (172 kDa), +3 FAF-BSA (238 kDa), and +4 FAF-BSA (304 kDa). Smearing
in the separating zone was due to the interaction of the PEG backbone with the polyacrylamide
gel as well as variability of the specific lysine residue activated by the DIBO reagents.
Manufacturer specifications quote the upper limit of separation for these gels at 300 kDa for nonPEGylated proteins. It is inferred that material retained in the stacking zone consists of a
minimum of five FAF-BSA molecules attached to the PEG8 backbone with a MW of
approximately 370 kDa.
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Figure 25. Electrophoretic separation of species of bovine serum albumin PEGylated via strainpromoted azide-alkyne click chemistry. Lane 1: FAF-BSA; Lane 2-3: BSAx-123t-PEG8; Lane 45: BSAx-PEG4-123t-PEG8; Lane 6: High molecular weight marker.
The speciation of purified PEGylated BSA was examined by AUC. The majority of the
PEGylated species generated with both activators were complexes containing BSA2-4. These
species accounted for 55% of BSAx-123t-PEG8 (Figure 26) and 65% of BSAx-PEG4-123t-PEG8
(Figure 27). BSA5-7-R-123t-PEG8 conjugates were present in much lower concentrations, making
up 31% and 14% of short and long activator species, respectively. The shorter DIBO-BSA
resulted in 8% BSA1 species while the longer DIBO-PEG4-BSA generated 19%. The peaks
found at S20,w values greater than 15 S are thought to be a mixture of BSA8-R-123t-PEG8 species
and complexes formed from over-activated protein.
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Figure 26. Analytical ultracentrifugation analysis of BSAx-123t-PEG8. % Area Count values are
the percent of PEGylated species only. nr: not reported; n/a: not applicable.
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Figure 27. Analytical ultracentrifugation analysis of BSAx-PEG4-123t-PEG8. % Area Count
values are the percent of PEGylated species only. nr: not reported; n/a: not applicable.
AUC results corresponded well with the SDS-PAGE analysis. Each purified sample
contained BSA1-R-123t-PEG8 with a much higher degree of BSA2-4-R-123t-PEG8. Higher
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molecular weight material was present but a lower concentration. The longer DIBO-PEG4-NHS
generated only slightly more PEGylated species than DIBO-NHS based on SEC data. However,
the distribution of those species was smaller, generating a more homogenous final product.
Ligand Binding Capabilities
To compare the effects of PEGylation on the ability of conjugated BSA to bind ligands,
fluorescent emission intensity of Trp213 was monitored. The ability of PEGylated species to
bind ligands in DS2 was probed with NPX. Crystal structures of de-fatted bovine, equine, and
leporine serum albumins complexed with NPX have been reported (Bujacz et al., 2014). In each
species of serum albumin, NPX preferentially binds to DS2. A second molecule of NPX binds to
fatty acid binding site 6. In leporine serum albumin, a tertiary site for NPX is found in a
superficial cleft in subdomain IIIA while in BSA, the tertiary binding site is DS1. Experimental
values for NPX in the presence of FAF-BSA, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8
were consistent with published values (Table 6). NPX was tightly bound by all species of BSA.
Table 6. Association Constants (Ka) and Number of Binding Sites (n) for BSAx-123t-PEG8 and
BSAx-PEG4-123t-PEG8 for Sulfamethoxazole and Naproxen.
SMZ
Sample
FAF-BSA
BSAx-123t-PEG8
BSAx-PEG4-123t-PEG8
Lit. values1,2

3

-1

NPX
7

Ka (x10 M )

n

Ka (x10 M-1)

n

2.03 ± 0.18
0.39 ± 0.29
0.15 ± 0.06

0.9 ± 0.1
0.8 ± 0.1
0.8 ± 0.05

0.40 ± 0.13
0.79 ± 0.61
3.55 ± 1.6

0.4 ± 0.1
2.4 ± 1.1
0.9 ± 0.2

3.55-15.6

0.9-1.0

0.12-3.70

0.6-3

1

SMZ values were published by Naik et al. (2009; 2015), Rajendiran & Thulasidhasan (2015), and Wang et al.
(2014).
2

NPX values were reported by Banerjee et al. (2006), Bou-Abdallah et al. (2016), Fielding et al. (2005), and Honoré
& Brodersen (1984). Bujacz et al. (2014) have reported a crystal structure (PDB ID: 4OR0) for BSA complexed
with three NPX molecules.
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Binding of NPX to FAF-BSA, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 showed
similar trends (Figure 28). BSA in the absence of NPX had a maximum emission wavelength at
344 nm. With increasing amounts of NPX, a red shift resulted in a maximum at 350 nm. This is
consistent with binding to a site adjacent to the fluorophore. In this case, the fluorophore studied
was Trp213 found in Domain IIA at the mouth of DS1. As ligand binds to DS2, slight
conformational changes exposed Trp213 to the solvent, causing a red shift.
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Figure 28. Fluorimetric spectra and non-linear regression of BSAx-123t-PEG8 and BSAx-PEG4123t-PEG8 in the presence of naproxen. Spectra for (a) BSAx-PEG4-123t-PEG8 and
(b) FAF-BSA in the presence of increasing concentrations of NPX. BSAx-123t-PEG8 spectra
followed similar trends as both FAF-BSA and BSAx-PEG4-123t-PEG8. (c) Non-linear regression
analyses for FAF-BSA (black ¯), BSAx-123t-PEG8 (blue r), and BSAx-PEG4-123t-PEG8
(orange ). Experimental data is represented as symbols while calculated data points are lines.
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DS1, however, appears to be greatly affected by the covalent attachment of PEG8. FAFBSA values were similar to published values for both Ka and n for SMZ studies (Table 6).
However, both BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8 demonstrated a greatly reduced
affinity for SMZ. Spectra for all forms of BSA followed similar trends (Figure 29). Intensities
decreased as SMZ concentration increased. The signal from Trp213 was quenched in the
presence of the ligand though it was not tightly bound in either form of PEGylated BSA.
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Figure 29. Fluorimetric spectra and non-linear regression of BSAx-R-123t-PEG8 in the presence
of sulfamethoxazole. Spectra for (a) BSAx-123t-PEG8 and (b) FAF-BSA in the presence of
increasing concentrations of SMZ. BSAx-PEG4-123t-PEG8 spectra followed similar trends as
both FAF-BSA and BSAx-123t-PEG8. (c) Non-linear regression analyses for FAF-BSA (black
¯), BSAx-123t-PEG8 (blue r), and BSAx-PEG4-123t-PEG8 (orange ). Experimental data is
represented as symbols while calculated data points are lines.
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Similar results were seen for PEGylation at Cys34 with maleimido-PEG8. Upon
modification of this single residue in Domain IA, the affinity for SMZ was reduced to 0.19 x103
M-1. It was hypothesized that conformational changes induced by PEGylation at Cys34 altered
the structure of DS1 which is found in Domains IB and IIA. The conditions employed for
SPAAC PEGylation allow for selective modification of lysines, but do not preferentially alter
specific lysines on the surface of BSA. Given the results from the modification of Cys34, it is
possible that lysines in Domain I are preferentially altered by DIBO-R-NHS activators.
Conclusions
The conjugation of BSA onto a PEG8 backbone via SPAAC proved successful using both
forms of DIBO activator. The PEGylation process proved to be most dependent on the ratio of
DIBO-BSA:N3-PEG8 with an optimal reaction ratio of 16:1.
The shorter DIBO-NHS PEGylated an average of 23% FAF-BSA. The extended DIBOPEG4-NHS yielded only slightly more product at 25%. The additional 14 Å was of little
assistance in terms of yield. The longer activating agent did, however, produce a more
homogenous final product, generating a majority of BSA2-4-R-123t-PEG8 species.
In terms of ligand binding capabilities, neither activating agent greatly affected BSA’s
ability to bind NPX, a model DS2 ligand. DS1 was affected by PEGylation as evidenced by
greatly reduced association constants.
The PEGylation procedure proved to be successful regardless of the activating agent.
High molecular weight complexes of FAF-BSA were still capable of binding ligands to one of
the main drug binding sites. These complexes show promise as a possible drug delivery method.

CHAPTER V
STUDIES ON THERMAL STABILITY AND
THE EFFECTS OF PASTEURIZATION ON
PEGYLATED MULTI-ALBUMIN COMPLEXES
Introduction
PEGylation has become a common method of increasing circulatory lifetimes of protein-based
therapies. Due to increased hydrodynamic volume conferred by the attachment of a polyethylene
glycol (PEG) backbone, the PEGylated complexes appear several times larger than molecular
weight would suggest (Plesner, Fee, Westh & Nielsen, 2011; Veronese, Mero & Pasut, 2009).
Increased size allows the particle to escape elimination and remain in circulation for longer
periods of time.
In order to increase solubility and provide protection for hydrophobic drugs, serum
albumins have been incorporated into drug carriers (Anhorn, Wagner, Kreuter, Langer & von
Briesen, 2008; Desai, 2008). Bovine serum albumin (BSA) contains a multitude of binding sites
which are tailored for endogenous molecules including fatty acids and heavy metals
(Bhattacharya, Grüne & Curry, 2000; Rózga, Sokołowska, Protas & Bal, 2007). Fatty acid
binding pockets, have been found to bind drugs but are typically secondary or tertiary options.
The primary hydrophobic cavities for drug binding were initially characterized by Sudlow et al.
(1975, 1976). Deemed Drug Sites I and II (DS1 and DS2), these sites are able to house a variety
of ligands (Ghuman et al., 2005; Yamasaki, Chuang, Maruyama & Otagiri, 2013).
84

85
DS1 is found at the interface of Domains IB and IIA while DS2 resides in Domain IIIA. Access
to these sites is controlled via flexing of the local tertiary structure.
BSA contains three highly helical domains (I, II, and III), each divided into two
subdomains (A and B) which are connected by long loops. Conformational flexibility of each
domain is conferred by helical bending and subdomain orientation is controlled by movement of
the loops. These types of movements open and close the various binding sites dotted throughout
the structure.
While the exterior of albumin is somewhat flexible, the interior of the protein is rigidly
maintained via 17 disulfide bridges. Subdomain A is stapled together by four of these while two
bridges stabilize subdomain B. An exception is Subdomain IA, which contains only three bridges
(Bujacz, 2012). A single free cysteine at position 34 is found on the surface of Domain I. This
superficial residue allows for selective, covalent attachment of a PEG chain.
Modifications of cysteines are often made via thiol-maleimide reactions, resulting in a
thioether linkage (Anhorn et al., 2008; Manjula et al., 2003; K. D. Webster et al., 2017). This
class of reaction has become attractive due to typically simple reaction conditions as it can
readily proceed in an aqueous environment and requires neither catalyst nor high temperatures.
In addition to this free cysteine, 59 lysines are scattered throughout BSA. Terminal amino
groups allow for modification with a number of different functional groups. One of the more
common reactions is via an N-hydroxysuccinimide (NHS) ester (Cline & Hanna, 1988). The
reactivity between NHS and lysine provides a convenient way to anchor another functional
group to the protein.
The abundance and easy access to these lysines allows for attachment of a foreign moiety
without the need for recombinant techniques. Strain-promoted azide-alkyne cycloaddition
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(SPAAC), a class of “click” chemistry, results a highly stable 1,2,3-triazole linker. Additionally,
both azide and alkyne are biorthogonal in that they are absent from nature and non-reactive with
naturally-occurring functional groups (Agard, Prescher & Bertozzi, 2004; Baskin & Bertozzi,
2009). By using the NHS-lysine reaction, a strained alkyne may be covalently attached to BSA.
PEG functionalized with the complimentary azido moiety may then be reacted with the alkyneactivated BSA to link the two molecules.
PEGylation, while providing many benefits to the modified protein, have also been
shown to affect thermal stability, which may be described by the temperatures of denaturation
(Tm) and aggregation (Tagg). Tm is the temperature at which a protein is 50% unfolded (K. W.
Olsen, 1994). Tagg describes the ability of both native and non-native forms of a protein to form
oligomerize (Plesner et al., 2011; Wetzel et al., 1980). Both are important parameters to consider
during the development of protein-based drug delivery systems as they factor into shelf-life and
terminal sterilization.
In the case of BSA, typical Tm is approximately 82oC as determined by differential
scanning calorimetry (Plesner et al., 2011). Attachment of a single linear 40 kDa PEG chain at
Cys34, lowered Tm to 80oC. Tagg, on the other hand, increased upon PEGylation. Unmodified
BSA aggregated at 71oC while the 40 kDa PEG-BSA species had a Tagg of 82oC.
Steam sterilization, or autoclaving, is the most common approach used in pharmaceutical
production. Materials are heated to 121oC at 1.5 bar for a minimum of 15 minutes. These
conditions are likely to denature protein components. For this reason, protein-based formulations
are sterilized aseptically, an approach where each component is sterilized individually before
preparation of the final product (Baez & Assaf-Anid, 2008; Yaman, 2001).
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Albumin-based components are pasteurized at 60 C for ten hours. In order to maintain
helicity, the stabilizing reagents N-acetyl-L-tryptophan (NAT) and sodium caprylate are included
at mole ratios of 5.5:1 stabilizer:albumin (Anraku et al., 2004; Christiansen & Skotland, 2010;
Farcet, Kindermann, Modrof & Kreil, 2012; Gellis et al., 1948).
High concentrations of these stabilizers have been implicated in the reduced efficacy of
albumin solutions administered to patients with impaired liver function. For these patients,
albumin, which is produced in the liver, is typically found at extremely low concentrations.
Exogenous albumin, which has been pasteurized with NAT and caprylate, is often administered
intravenously to compensate. Both reagents have been shown to have an affinity for DS2, a site
also shared by metabolites commonly formed at high levels in patients with liver disease (Kawai
et al., 2017).
In healthy individuals, NAT and caprylate bind to albumin. Albumin production is
unimpaired and routine transport of NAT, caprylate, and other metabolites is unaffected. In
impaired individuals, elevated levels of these toxins are often found due to direct competition
with stabilizers for a single high affinity binding site (Stange et al., 2011).
These additives also pose a potential problem for production of albumin-based drug
delivery systems. Their preference for DS2 results in competition between NAT, caprylate, and
the drug molecule being administered. For naproxen (NPX), a known DS2 ligand, affinity was
40 times lower in pharmaceutical-grade albumin solutions (i.e. pasteurized with NAT and
caprylate) than in research-grade albumin (i.e. un-pasteurized) (H. Olsen, Andersen, Nordbo,
Kongsgaard & Bormer, 2004).
In this study, the effects of PEGylation on the thermal stability of BSA were examined.
Three PEGylated BSA complexes were prepared. In the first case, native Cys34 of BSA was
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used as a site of direct attachment of an eight-armed PEG backbone with terminal maleimides
(Mal-PEG8) resulting in a thioether linker. For the two others, BSA were attached to PEG8 via
SPAAC click chemistry. BSA was “activated” with either a short- or long-chain
dibenzocyclooctyne-functionalized N-hydroxysuccinimidyl ester (DIBO-NHS; DIBO-PEG4NHS). Activated BSA were attached to an azido-functionalized PEG8 backbone (N3-PEG8)
resulting in a 1,4-disubstituted, 1,2,3-triazole. Changes in the absorbance at 300 nm as a function
of temperature were used to calculate Tagg while Tm was determined for each PEG species by
circular dichroism (CD). PEGylated BSA, pre-loaded with NPX, were pasteurized in the absence
of NAT and caprylate to determine if a combination of PEGylation and bound ligand would
allow for omission of these stabilizing compounds.
Materials and Methods
Materials
Lyophilized BSA (Product Number A7906), DIBO-NHS (761524), DIBO-PEG4-NHS
(764019), NPX (N8280), and all reagents not detailed were purchased from Sigma-Aldrich.
Methods
All experiments were carried out in 50 mM 4-Morpholinepropanesulfonic acid/0.15 M
NaCl pH 7.2 (MOPS/NaCl) buffer unless otherwise noted. Fast protein liquid chromatography
(FPLC) separations were performed on an ÄKTAprime plus chromatography system (Amersham
Biosciences; 11001313) with MOPS/NaCl mobile phase. Resulting fractions were concentrated
with 30 kDa molecular weight cut-off centrifuge filters (Sartorius; VS2022). Absorbance values
were obtained on an Agilent 8453 UV-visible Spectroscopy System at 280 nm. Concentrations of
BSA were calculated with an extinction coefficient of 43.824 mM-1 cm-1 and a molecular weight
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of 66,430 Da (Hirayama, Akashi, Furuya & Fukuhara, 1990; "Thermo Scientific: Extinction
Coefficients," 2013).
Fatty acid removal. Fatty acid-free BSA (FAF-BSA) was prepared via an activated
charcoal method (Chen, 1967). In short, BSA was dissolved in MOPS/NaCl. The solution was
acidified to pH 3 and stirred on ice with 20-40 mesh particle size activated charcoal in order to
remove any bound fatty acids. Charcoal was pelleted at 10,000 rpm and the supernatant was
filtered through 0.2 µm cellulose filters to remove any remaining carbon. The de-fatted albumin
solution was returned to pH 7.2 before further purification. Dimers were removed by size
exclusion chromatography (SEC) on a pre-packed 120 mL 60 cm x 16 mm S300 FPLC column
(GE Healthcare; 17-1167-01).
PEGylation of FAF-BSA. Table 7 details the nomenclature used to discuss these
reactions. Cys34, requiring no further activation, was attached to PEG8 with a thioether (te)
linkage formed by reaction with Mal-PEG8. For SPAAC reactions, the complimentary azide for
all DIBO-functionalized BSA reactions was N3-PEG8, resulting in a 1,2,3-triazole (123t).
Table 7. Nomenclature for PEGylation of Bovine Serum Albumin via Thiol-Maleimide and
Strain-Promoted Azide-Alkyne Cycloaddition Reactions.
Activator
n/a

Activated BSA
n/a

PEG8

PEG Product

Thiol-Maleimide
Mal-PEG8

BSAx-te-PEG8

Strain-Promoted Azide-Alkyne Cycloaddition
DIBO-R-NHS
(generic)
DIBO-NHS
(short)
DIBO-PEG4-NHS
(long)

DIBO-R-BSA
DIBO-BSA
DIBO-PEG4-BSA

BSAx-R-123t-PEG8
N3-PEG8

BSAx-123t-PEG8
BSAx-PEG4-123t-PEG8
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PEGylation of Cys34. 40 kDa Mal-PEG8 (Creative PEGworks; PSB-864) was dissolved
in MOPS/NaCl and added to 1 mM FAF-BSA at 8:1 FAF-BSA:Mal-PEG8. The solution was
allowed to incubate at room temperature for one week with constant stirring.
PEGylation with SPAAC. Conjugation of BSA molecules onto a 40 kDa N3-PEG8
backbone required two steps, activation and PEGylation. Activation involves the attachment of a
DIBO functional group onto BSA via reaction between an NHS-ester and the amino side-chain
of lysine. DIBO-NHS and DIBO-PEG4-NHS stocks were prepared in dry dimethyl sulfoxide and
added to 1 mM FAF-BSA to give a final ratio of 1:1 DIBO-R-NHS:FAF-BSA. Introduction of
DIBO-R-NHS was made in small aliquots with mixing between additions to avoid BSA
denaturation due to the organic solvent. After two hours at room temperature, excess activator
was removed by triple-rinsing the sample through 30 kDa centrifuge filters ("Thermo Scientific:
NHS-Azide and NHS-Phosphine Reagents," 2014).
N3-PEG8 (Creative PEGworks; PSB-884) dissolved in MOPS/NaCl was added to 1 mM
DIBO-activated FAF-BSA at 16:1 DIBO-R-BSA:N3-PEG8. The solution was allowed to
incubate at room temperature for one week with constant stirring.
Purification of PEGylated BSA. PEGylated FAF-BSA was purified via a two-phase SEC
separation. The bulk of unreacted FAF-BSA was removed by way of an S300 FPLC column, the
remainder via a 320 mL 60 cm x 26 mm S500 column (GE Healthcare; 28-9356-07).
Spectroscopic evaluation of aggregation. Tagg was determined by monitoring
absorbance at 300 nm as samples were heated from 30 oC to 100oC over two hours. Samples
were initially assayed in MOPS/NaCl. Due to a lack of aggregation of the PEGylated samples,
the buffer was further modified with 1.5 M Guanidinium chloride (GdmCl) and 0.4% (v/v) 2Mercaptoethanol (βME). The maximum temperature was held for an additional 20 minutes to
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ensure the maximum absorbance had been reached. Tagg was calculated following the two-state
method detailed by Olsen (1994).
Additionally, the absorbance at 300 nm was monitored for samples prepared in
MOPS/NaCl/0.4% βME/1.5 M GdmCl at 30oC for 2 hours 20 minutes. This ensured that
unfolding was not due solely to the high concentrations of denaturing reagents.
Circular dichroic evaluation of denaturation. The effect of PEGylation on the thermal
stability of each of these complexes was determined by CD. Samples were diluted to 0.15 mg/mL
in 50 mM MOPS pH 7.2 and heated from 30oC to 90oC in an Olis DSM 20 CD
Spectrophotometer. Spectra were collected at 30, 40, 50, 60, 63, 66, 70, 80, and 90oC over the
range of 190-260 nm with a 1 nm step-size. Helicity was calculated with DichroWeb (Whitmore
& Wallace, 2008) and the analysis program CDSSTR (Sreerama & Woody, 2000). Inclusion of a
crystal structure for human serum albumin (Wardell et al., 2002) allowed for use of reference set
SP175 (Janes, 2009; Lees, Miles, Wien & Wallace, 2006). Helicity at each temperature was
compared to that of 30oC to calculate the % Remaining Helicity. A plot of % Remaining Helicity
as a function of temperature was used to calculate Tm.
Pasteurization studies. To determine the necessity for the stabilizing agents NAT and
caprylate in pasteurization, PEGylated BSA samples were diluted to 0.15 mg/mL in 50 mM MOPS
pH 7.2 and incubated at 60oC for ten hours in the presence and absence of NPX. A 150 mM NPX
stock prepared in methanol was further diluted to a working stock concentration of 0.5 mM with
MOPS buffer. Samples were loaded at a mole ratio of 3:1 BSA:NPX prior to incubation. Control
samples were held at 4oC for the duration of all experiments. All samples were brought to room
temperature before further analysis.
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Circular dichroic evaluation of secondary structure. CD spectra of pasteurized samples
were collected at 30oC under the conditions described above. For neat solutions of NPX, no
signal was observed for NPX under these conditions.
Fluorimetric evaluation of naproxen binding. Binding studies were performed on a
Photon Technology International fluorimeter using Felix software (version 1.1). NPX was
studied to determine if pasteurization in the absence of stabilizing agents affected ligand binding
in DS2. The number of binding sites (n) and the association constant (Ka) were calculated.
30 kDa centrifuge filters were used to concentrate pasteurized BSA and exchange MOPS
buffer for 10 mM phosphate buffer pH 7.0. 30 µM BSA stock solutions were prepared in
phosphate buffer. NPX was dissolved in methanol to a final stock concentration of 45 mM. A
working NPX stock was prepared at 0.15 mM by dilution with phosphate buffer. Monitoring
emission between 300-380 nm upon excitation at 295 nm at 25oC, aliquots of working NPX
stocks were titrated into a 0.725 µM BSA solution to a final concentration of 3 µM NPX.
NPX blanks at each concentration were necessary to account for any fluorescence due to
the ligand itself. NPX showed strong emission with maxima at approximately 350 nm.
Particularly at high concentrations, NPX signal obscured the BSA maxima which ranges from
344 to 350 nm.
Non-linear regression analyses were carried out using The Gnumeric Spreadsheet (version
1.10.16) ("The Gnome Project: The Gnumeric Spreadsheet: Free, Fast, Accurate - pick any
three," 2011) and a modified Hill equation. In order to normalize samples, fractional intensities
(FrInt) were used in place of raw intensities.

FrInt =

FrInt ()* – FrInt (,- ∗ Ligand
K -5 + Ligand -

FrInt =

(Int , 89 :,;)-5 − Int = 89 :,;)-5 )
(Int ()* 89 :,;)-5 − Int = 89 :,;)-5 )
K) =
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Results and Discussion
Temperature of Aggregation (Tagg)
Initial experiments were performed in MOPS/NaCl (Figure 30a). However, neither FAFBSA nor any of the PEGylated species peaked under these conditions. In order to further weaken
the secondary structure of BSA, 0.4% (v/v) βME was added to MOPS/NaCl to reduce the 17
disulfide bridges of BSA. FAF-BSA and BSAx-123t-PEG8 denatured and aggregated under these
conditions but BSAx-te-PEG8 and BSAx-PEG4-123t-PEG8 still did not peak (Figure 30b).
MOPS/NaCl/0.4% (v/v) βME was further modified with 1.5 M GdmCl. With a high
concentration of a strong chaotrope and reducing agent, all species of BSA peaked (Figure 30c).
The decrease in signal after maximum absorbance was due to aggregates precipitating and
settling. Samples incubated at 30oC for the full run-time showed no change in absorbance at 300
nm, indicating that denaturation was not due solely to the presence of high concentrations of
GdmCl and βME.
FAF-BSA had the lowest Tagg of 72.5oC (Table 8). BSAx-123t-PEG8 (91.8oC) and BSAxPEG4-123t-PEG8 (92.9oC) had significantly higher Tagg values with similar peak shapes. BSAxte-PEG8 reached the 50% mark at a higher temperature (77.5oC) than FAF-BSA but the signal
began increasing at a lower temperature.

94
Table 8. Temperatures of Denaturation and Aggregation for PEGylated BSA Species.
Sample

Tagg (oC)

Tm (oC)

ΔTm (oC)

FAF-BSA
BSAx-te-PEG8
BSAx-123t-PEG8
BSAx-PEG4-123t-PEG8

72.5 ± 5.3
77.5 ± 5.3
91.8 ± 2.0
92.9 ± 2.6

81.2 ± 4.1
77.7 ± 0.9
69.4 ± 3.6
76.0 ± 3.2

0
-3.5
-11.8
-5.2

The broadening of the BSAx-te-PEG8 peak was attributed to the dissolution of the
thioether linker in the presence of high concentrations of excess thiol in the form of βME.
Studies have explored the dissociation of antibody-drug conjugates due to this phenomenon
(Alley et al., 2008; Shen et al., 2012). Following intravenous administration to mice, the
thioether linkage reverted back to thiol-containing antibody and maleimido-functionalized drug,
which covalently bound to Cys34 of native serum albumin. To stabilize the thioether,
bromination of the maleimide moiety and hydrolysis of the succinimide to succinic acid have
been explored and provide intriguing options (Fontaine, Reid, Robinson, Ashley & Santi, 2015;
Smith et al., 2015).
The shape of BSAx-te-PEG8 in Figure 30c is due to the gradual dissolution of the
thioether and subsequent denaturation and aggregation of the released BSA. The triazole of
BSAx-R-123t-PEG8 species provides a thermally stable linker and results in a sharper peak.
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Figure 30. Change in absorbance as a function of temperature for the determination of Tagg. (a)
Aggregation was minimal in MOPS/NaCl. (b) Addition of βME to the buffer resulted in
aggregation of some species. (c) All samples aggregated at measurable temperatures in 50 mM
MOPS/0.15 M NaCl/0.4% βME/1.5 M GdmCl pH 7.2. FAF-BSA (black); BSAx-te-PEG8 (red);
BSAx-123t-PEG8 (blue); BSAx-PEG4-123t-PEG8 (orange). Dashed lines correspond to 50%
aggregation.
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Temperature of Denaturation (Tm)
CD spectra for all species of BSA showed characteristic minima at 210 nm and 220 nm at
30oC, indicating highly α-helical protein (Figure 31). The helicity for each species ranged
between 59-63% which is in agreement with published values of 56-66% (Das et al., 2017;
Moriyama et al., 2008). As temperature increased, these valleys became less defined and helicity
decreased.
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Figure 31. Temperature-induced changes in circular dichroic spectra. Definition of valleys at 210
and 220 nm of FAF-BSA was lost as temperature increased. BSAx-te-PEG8, BSAx-123t-PEG8,
and BSAx-PEG4-123t-PEG8 followed this same trend.
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Tm was calculated as the temperature at which 50% of the original helical content was
lost. For FAF-BSA and all three types of PEGylated complexes, helicity slowly decreased up to
60oC where the values dropped rapidly to minima at 90oC (Figure 32).
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Figure 32. Change in helicity as a function of temperature for the determination of Tm. (a) FAFBSA; (b) BSAx-te-PEG8; (c) BSAx-123t-PEG8; (d) BSAx-PEG4-123t-PEG8. n/a: not applicable.
Unmodified FAF-BSA had the highest Tm at 81.2oC (Table 8). This is in agreement with
the published value of 82.5oC (Plesner et al., 2011).
The effect seen with PEGylated species on Tm is not due to the type or size of PEG
backbone used as evidenced by BSAx-te-PEG8. For modifications at Cys34, neither a straightchain nor branched PEG caused a significant change in denaturation temperature. Attachment of
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a branched 40 kDa PEG8 backbone resulted in a decrease in Tm by 3.5 C, which is similar to the
o

published 2oC decrease with a straight chain 40 kDa Mal-PEG. As reported by Plesner et al.
(2011), the decrease in Tm of PEGylated BSA was approximately 2oC for all species of linear 560 kDa PEG, regardless of the molecular weight of the PEG chain.
The drastic change in lysine-modified PEGylated BSA may be related to the proximity of
DIBO to the surface of the protein. Modification of a lysine with the extended DIBO-PEG4-NHS
activator resulted in a decrease in Tm by 5.2oC while the largest difference of 11.8oC was seen
with the shorter DIBO-NHS activator. DIBO, being a bulky, hydrophobic group, is capable of
altering the surface chemistry of BSA. This is likely the case for BSAx-123t-PEG8, where the
activating agent lacks a spacer. In BSAx-PEG4-123t-PEG8, the added space between DIBO and
the surface of BSA lessened the effect of hydrophobic interactions. Addition of a nonpolar patch
onto the exterior of BSA greatly affected solvent interaction and may have promoted
denaturation.
Effects of Pasteurization on Secondary Structure and Ligand Binding
The effects of pasteurization without stabilizing reagents was monitored by CD and NPX
binding studies. In the absence of NPX, up to 18% of total helicity was lost (Figure 33). BSAxPEG4-123t-PEG8 lost only 7%, further strengthening the argument that increasing the distance
between protein and PEG8 may further stabilize the complex.
Helicity was maintained after addition of NPX at 4oC. Upon pasteurization, all samples
consistently lost 7-10% of the original helicity. NPX has been found to bind with an association
constant (Ka) on the order of 107 M-1. Addition of a tightly bound ligand proved to stabilize all of
these species of BSA. This is most significant for BSAx-te-PEG8 as helicity was restored to
levels comparable to BSAx-R-123t-PEG8 species.
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A significant amount of helicity was lost upon pasteurization of BSA species without
ligand bound. Ligand binding capabilities of these samples was determined using NPX to probe
the high affinity site DS2.
Prior to pasteurization, all samples were able to tightly bind NPX with Ka values in the
range of 107 M-1 which correspond well with published values (Figure 34). After pasteurization,
these values decreased by several fold for all species of BSA except BSAx-123t-PEG8. This
suggests major structural changes that greatly affect DS2.
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Figure 34. Non-linear regression analyses of fluorimetric assays of PEGylated bovine serum albumin before and after pasteurization.
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Conclusions
Attachment of a PEG chain to BSA clearly affected the thermal stability of the protein.
PEGylation, while lowering Tm, increased Tagg. Use of a short activating agent resulted in
alteration of the surface of BSA due to interaction with the hydrophobic DIBO group, resulting
in a marked decrease in Tm. Added space between the protein surface and the DIBO group
lessened the effect of the nonpolar DIBO.
Mal-PEG8 attached at the lone free thiol of BSA showed an increase in Tagg but peak
broadening may be due to the dissolution of the thioether linker. Both BSAx-123t-PEG8 and
BSAx-PEG4-123t-PEG8 effectively blocked aggregation, as seen by considerably higher Tagg.
PEGylation and pre-loading of complexes with a high affinity ligand are insufficient
measures for maintenance of helicity during pasteurization. Sterilization of PEG species in the
absence of ligand resulted in significant loss of helicity along with reduction of ligand binding
capabilities. Pre-loading PEGylated BSA species mitigated these losses but still resulted in some
loss of helicity. A combination of effects is needed to stabilize the complex. Binding NPX prior
to pasteurization helps to prevent denaturation while PEGylation if more effective at preventing
aggregation.

CHAPTER VI
GENERAL CONCLUSIONS AND FUTURE RESEARCH
General Conclusions
Three different species of PEGylated BSA have been developed using thiol-maleimide and
strain-promoted azide-alkyne cycloaddition “click” chemistries. All three products were mixtures
of predominantly BSA2-4-R-PEG8 with some amount of unmodified BSA and higher molecular
weight species. BSAx-PEG4-123t-PEG8 was the most homogeneous sample, containing the
fewest higher molecular weight species while BSAx-te-PEG8 was the least homogeneous,
containing a large number of higher molecular weight species. The wider distribution of BSAxte-PEG8 was unexpected due to the presence of a single PEGylation site at Cys34. Formation of
higher molecular weight species was attributed to the side-reaction of Mal-PEG8 with native
lysines.
All species of BSAx-R-PEG8 demonstrated similar ligand binding capabilities. DS2 was
unaffected as association constants for naproxen were within the range of reported values for
unmodified BSA. Interactions between DS1 and sulfamethoxazole, however, were greatly
weakened by PEGylation. While the number of binding sites for each remained in agreement
with the literature, association constants were several times smaller for PEGylated BSA than
unmodified FAF-BSA.
The difference in effects of PEGylation on these binding sites was likely due to the
placement of the PEG backbone. In the case of BSAx-te-PEG8, the main site of modification was
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Cys34 in Domain IA. DS1 is located at the interface of Domains IB and IIA. Conformational
changes due to PEGylation in the same domain altered the cavity of DS1 and greatly reduced
binding capabilities. DS2, on the other hand, is located in Domain IIIA. Modifications made at
Cys34 appear to have little to no effect on ligand binding to DS2.
For BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8, the exact site of modification is
unknown as both activating agents were attached by an NHS-lysine reaction. BSA contains 59
lysines. 20 appear in Domains I and III while 19 are found in Domain II. Given the high number
and even distribution of potential sites of modification, a preference for a given domain is not
readily apparent. However, similar drug binding profiles between BSAx-te-PEG8 and BSAx-R123t-PEG8 of this study suggest a preference for modification of Domain I.
Temperature of unfolding was most affected by activation with the short DIBO-NHS.
Both BSAx-te-PEG8 and BSAx-PEG4-123t-PEG8 showed similar denaturation curves to
unmodified FAF-BSA. BSAx-123t-PEG8 was the least thermally stable of the complexes. This
was attributed to the proximity of the hydrophobic DIBO group to the surface of BSA altering
solvent interaction. Moving the DIBO further from the protein surface, as in BSAx-PEG4-123tPEG8, or complete elimination of DIBO (BSAx-te-PEG8), restored Tm to similar values for that
of unmodified FAF-BSA.
The reverse was found for the temperature of aggregation. BSAx-R-123t-PEG8 species
aggregated at much higher temperatures than either FAF-BSA or BSAx-te-PEG8. While Cys34
modified FAF-BSA had a higher Tagg, the signal began increasing at a much lower temperature
than FAF-BSA, likely due to the dissolution of the thioether linker. This instability was
potentially due to the high concentration of excess thiol from 2-Mercaptoethanol in the
denaturing buffer.
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PEGylation and pre-loading of a high affinity DS2 ligand proved insufficient to allow for
omission of stabilizing agents used in the pasteurization process. A significant decrease in
helicity was seen for all PEGylated BSA species following pasteurization in the absence of
naproxen. When sterilized with naproxen bound, a moderate loss of helicity was seen for all
species of BSA. A combination of PEGylation and pre-loading the complex with a tightly bound
ligand reduced the denaturing effects of pasteurization but did not completely eliminate them.
Future Research
The future of this project may be aimed at answering four questions: 1) Can a
homogeneous BSAx-R-PEG8 product be generated with higher yields? 2) Can a fatty acid which
does not compete for DS2 be substituted for caprylate? 3) Can these PEGylated species
effectively release drugs? and 4) Does PEGylation affect cellular uptake?
The formation of three different forms of PEGylated BSA has been verified but the
production process may still be improved. Yields and homogeneity of the products are
potentially tied to the distance between BSA and the PEG8 backbone. An additional 14 Å
between BSA and PEG8 was gained by incorporation of a PEG4 linker into the activating agent.
This modification produced slightly higher yields and a more homogeneous final product.
Extension of the PEG arms is the easiest way to increase this distance. The largest available
eight-armed PEG is 40 kDa, each branch having an average molecular weight of 5 kDa which
corresponds to 113 subunits. By extending these branches, the congestion around the PEG
backbone will be relieved. Less steric hindrance would allow for BSA molecules to have easier
access to the terminal functional groups. The amount of PEGylated product generated would
increase while the number of different species formed would decrease.
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Caprylate, one of the stabilizing agents used in pasteurization, is a saturated eight-carbon
fatty acid (8:0) with an affinity for DS2 (Kawai et al., 2017). Oleate (18:1), palmitate (16:0), and
linoleate (18:2) account for the majority of bound fatty acids to human serum albumin (A. Saifer
& Goldman, 1961). One of these compounds may prove to be an alternative stabilizing agent.
BSA contains seven fatty acid binding sites (Bhattacharya, Grüne & Curry, 2000;
Rizzuti, Bartucci, Sportelli & Guzzi, 2015; Simard et al., 2005). Fatty acid site 5 (FA5) resides in
Domain III and contains hydrophilic features (Y400 and K524) at the entrance to the cavity
which interact with the polar head group of bound fatty acids. This cavity has been shown to
bind long chain fatty acids with the highest affinity of the seven sites (Rizzuti et al., 2015;
Simard et al., 2005).
DS2 of BSA is also located in Domain III with polar residues at Y410, R409, and S488.
Use of a single long chain fatty acid which preferentially binds to FA5 may provide a substitute
for caprylate in the pasteurization process. This would reduce competition for DS2, however, the
proximity of FA5 to DS2 may alter binding profiles. By binding to a site away from DS2,
thermal stability may be enhanced while maintaining ligand binding capabilities.
Also of interest is the ability to release bound drugs. Reported results show that these
PEGylated BSA species are able to bind ligands, if only in DS2. If addition of a DS2 ligand is
required before sterilization, the storage stability of the drug-BSA complex must be evaluated to
avoid dissociation of the complex before administration. Diffusion-based experiments
monitoring the effects of pH, temperature, time, etc. will provide information as to the shelf-life
of these formulated products.
Gp60 has been identified as a cell surface receptor for albumin and plays a key role in the
efficacy of the non-PEGylated albumin-based therapy Abraxane® (Desai, 2008; Schnitzer, 1992).
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Albumin-based nanoparticles prepared via conjugation of BSA with either polystyrene (Wang,
Tiruppathi, Cho, Minshall & Malik, 2011) or PEGylated liposomes (Thöle, Nobmann, Huwyler,
Bartmann & Fricker, 2002) were successfully endocytosed into cells in vitro. This suggests that
the degree of PEGylation in BSAx-te-PEG8, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 will
not necessarily inhibit gp60-mediated transcytosis. In order to evaluate the viability as drug
delivery systems, the ability of cells to endocytose these PEGylated complexes must be assessed.
These PEGylated species utilize more cost-effective components, require no specialized
equipment, and modify the albumin core at a bare minimum of sites. By maintaining albumin
close to its native form while conferring the benefits of PEGylation, potential alternatives to
current drug delivery systems and protein-based therapies have been developed.
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